Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Bal, A. Kumar (2008)
Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy.Tropical gastroenterology : official journal of the Digestive Diseases Foundation, 29 2
D. Maucort-Boulch, Catherine Martel, S. Franceschi, M. Plummer (2018)
Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwideInternational Journal of Cancer, 142
M. Donadon, L. Solbiati, L. Dawson, A. Barry, G. Sapisochin, P. Greig, S. Shiina, A. Fontana, G. Torzilli (2016)
Hepatocellular Carcinoma: The Role of Interventional OncologyLiver Cancer, 6
V. Schwarze, C. Marschner, W. Völckers, G. Figueiredo, J. Rübenthaler, Dirk-André Clevert (2020)
The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients.Clinical hemorheology and microcirculation
Benjamin Yan, Can Gong, Jie Song, T. Krausz, M. Tretiakova, E. Hyjek, H. Al-Ahmadie, V. Alves, S. Xiao, R. Anders, J. Hart (2010)
Arginase-1: A New Immunohistochemical Marker of Hepatocytes and Hepatocellular NeoplasmsThe American Journal of Surgical Pathology, 34
(Costentin C. Le dépistage du carcinome hépatocellulaire. Press Medicale [Internet]. 2017;46:381–5. https://linkinghub.elsevier.com/retrieve/pii/S0755498216303578)
Costentin C. Le dépistage du carcinome hépatocellulaire. Press Medicale [Internet]. 2017;46:381–5. https://linkinghub.elsevier.com/retrieve/pii/S0755498216303578Costentin C. Le dépistage du carcinome hépatocellulaire. Press Medicale [Internet]. 2017;46:381–5. https://linkinghub.elsevier.com/retrieve/pii/S0755498216303578, Costentin C. Le dépistage du carcinome hépatocellulaire. Press Medicale [Internet]. 2017;46:381–5. https://linkinghub.elsevier.com/retrieve/pii/S0755498216303578
K. Lokesh, T. Chaudhuri, K. Lakshmaiah, K. Babu, L. Dasappa, L. Jacob, M. Babu, A. Rudresha, L. Rajeev (2017)
Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.Indian journal of cancer, 54 3
(Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: Potential use for prognosis and diagnostic imaging. Oncotarget [Internet]. 2019;10:4149–60. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.27024)
Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: Potential use for prognosis and diagnostic imaging. Oncotarget [Internet]. 2019;10:4149–60. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.27024Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: Potential use for prognosis and diagnostic imaging. Oncotarget [Internet]. 2019;10:4149–60. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.27024, Tolkach Y, Goltz D, Kremer A, Ahmadzadehfar H, Bergheim D, Essler M, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: Potential use for prognosis and diagnostic imaging. Oncotarget [Internet]. 2019;10:4149–60. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.27024
P. Esquinas, A. Shinto, K. Kamaleshwaran, Jephy Joseph, A. Celler (2018)
Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scansEJNMMI Physics, 5
R. Mantravadi, D. Spigos, W. Tan, E. Felix (1982)
Intraarterial yttrium 90 in the treatment of hepatic malignancy.Radiology, 142 3
(Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20‐year outcome and prognostic factors. Liver Int [Internet]. 2012;32:1434–42. https://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2012.02838.x)
Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20‐year outcome and prognostic factors. Liver Int [Internet]. 2012;32:1434–42. https://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2012.02838.xShiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20‐year outcome and prognostic factors. Liver Int [Internet]. 2012;32:1434–42. https://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2012.02838.x, Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20‐year outcome and prognostic factors. Liver Int [Internet]. 2012;32:1434–42. https://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2012.02838.x
(GODT. International Report on Organ Donation and Transplantation Activities: Executive Summary 2017. [Internet]. 2017. http://www.transplant-observatory.org/download/2017-activity-data-report/)
GODT. International Report on Organ Donation and Transplantation Activities: Executive Summary 2017. [Internet]. 2017. http://www.transplant-observatory.org/download/2017-activity-data-report/GODT. International Report on Organ Donation and Transplantation Activities: Executive Summary 2017. [Internet]. 2017. http://www.transplant-observatory.org/download/2017-activity-data-report/, GODT. International Report on Organ Donation and Transplantation Activities: Executive Summary 2017. [Internet]. 2017. http://www.transplant-observatory.org/download/2017-activity-data-report/
N. Lepareur, V. Ardisson, N. Noiret, E. Boucher, J. Raoul, Bruno Clément, E. Garin (2011)
Automation of labelling of Lipiodol with high-activity generator-produced 188Re.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 69 2
B. Lambert, K. Bacher, L. Defreyne, F. Gemmel, H. Vlierberghe, J. Jeong, R. Dierckx, C. Wiele, H. Thierens, F. vos (2005)
188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46 1
(Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. JAMA Oncol [Internet]. 2018;4:661. http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.5847)
Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. JAMA Oncol [Internet]. 2018;4:661. http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.5847Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. JAMA Oncol [Internet]. 2018;4:661. http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.5847, Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. JAMA Oncol [Internet]. 2018;4:661. http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.5847
D. Woodfield (1986)
Hepatocellular carcinoma.The New Zealand medical journal, 99 795
T. Helmberger (2020)
Selective Internal Radiation TherapyDefinitions
(Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, et al. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Heal [Internet]. 2017;83:281–92. https://annalsofglobalhealth.org/articles/10.1016/j.aogh.2017.02.002)
Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, et al. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Heal [Internet]. 2017;83:281–92. https://annalsofglobalhealth.org/articles/10.1016/j.aogh.2017.02.002Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, et al. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Heal [Internet]. 2017;83:281–92. https://annalsofglobalhealth.org/articles/10.1016/j.aogh.2017.02.002, Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, et al. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Heal [Internet]. 2017;83:281–92. https://annalsofglobalhealth.org/articles/10.1016/j.aogh.2017.02.002
J. Yang, P. Hainaut, G. Gores, Amina Amadou, A. Plymoth, L. Roberts (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and managementNature Reviews Gastroenterology & Hepatology
(Chen D ‐S, Sung J ‐L. Serum alphafetoprotein in hepatocellular carcinoma. Cancer [Internet]. 1977;40:779–83. http://www.ncbi.nlm.nih.gov/pubmed/70268)
Chen D ‐S, Sung J ‐L. Serum alphafetoprotein in hepatocellular carcinoma. Cancer [Internet]. 1977;40:779–83. http://www.ncbi.nlm.nih.gov/pubmed/70268Chen D ‐S, Sung J ‐L. Serum alphafetoprotein in hepatocellular carcinoma. Cancer [Internet]. 1977;40:779–83. http://www.ncbi.nlm.nih.gov/pubmed/70268, Chen D ‐S, Sung J ‐L. Serum alphafetoprotein in hepatocellular carcinoma. Cancer [Internet]. 1977;40:779–83. http://www.ncbi.nlm.nih.gov/pubmed/70268
(Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int [Internet]. 2017;11:317–70. http://link.springer.com/10.1007/s12072-017-9799-9)
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int [Internet]. 2017;11:317–70. http://link.springer.com/10.1007/s12072-017-9799-9Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int [Internet]. 2017;11:317–70. http://link.springer.com/10.1007/s12072-017-9799-9, Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int [Internet]. 2017;11:317–70. http://link.springer.com/10.1007/s12072-017-9799-9
(Volk ML, Vijan S, Marrero JA. A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria. Am J Transplant [Internet]. 2008;8:839–46. http://doi.wiley.com/10.1111/j.1600-6143.2007.02138.x)
Volk ML, Vijan S, Marrero JA. A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria. Am J Transplant [Internet]. 2008;8:839–46. http://doi.wiley.com/10.1111/j.1600-6143.2007.02138.xVolk ML, Vijan S, Marrero JA. A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria. Am J Transplant [Internet]. 2008;8:839–46. http://doi.wiley.com/10.1111/j.1600-6143.2007.02138.x, Volk ML, Vijan S, Marrero JA. A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan Criteria. Am J Transplant [Internet]. 2008;8:839–46. http://doi.wiley.com/10.1111/j.1600-6143.2007.02138.x
Shanshan Wang, Anqiang Wang, Jianzhen Lin, Yuan Xie, Liangcai Wu, Hanchun Huang, J. Bian, Xiaobo Yang, Xueshuai Wan, Haitao Zhao, Jie-fu Huang (2017)
Brain metastases from hepatocellular carcinoma: recent advances and future avenuesOncotarget, 8
Di-yang Xie, Z. Ren, Jian Zhou, Jia Fan, Q. Gao (2020)
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.Hepatobiliary surgery and nutrition, 9 4
T. Yau, Vikki Tang, T. Yao, S. Fan, C. Lo, R. Poon (2014)
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.Gastroenterology, 146 7
Kristina Tzartzeva, Joseph Obi, N. Rich, N. Parikh, J. Marrero, A. Yopp, A. Waljee, A. Singal (2018)
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.Gastroenterology, 154 6
C. Wiele, M. Sathekge, B. Spiegeleer, Pieter Jonghe, L. Beels, A. Maes (2019)
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic ReviewInternational Journal of Molecular Sciences, 20
(Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol [Internet]. 2017;18:1624–36. https://linkinghub.elsevier.com/retrieve/pii/S1470204517306836)
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol [Internet]. 2017;18:1624–36. https://linkinghub.elsevier.com/retrieve/pii/S1470204517306836Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol [Internet]. 2017;18:1624–36. https://linkinghub.elsevier.com/retrieve/pii/S1470204517306836, Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol [Internet]. 2017;18:1624–36. https://linkinghub.elsevier.com/retrieve/pii/S1470204517306836
N. Nabavizadeh, Y. Jahangiri, R. Rahmani, Y. Tomozawa, Yindee Geeratikun, Yiyi Chen, A. Hung, C. Degnin, K. Farsad (2020)
Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis.AJR. American journal of roentgenology
E. Boucher, E. Garin, Anne Guylligomarc'h, D. Olivié, K. Boudjema, J. Raoul (2007)
Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 82 1
Yeshika Sharma, Michael Weaver, D. Ludwig, Kathryn Fowler, N. Vachharajani, W. Chapman, J. Crippin (2017)
Serum alpha‐fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resectionSurgery, 163
(Sangro B, Salem R. Transarterial Chemoembolization and Radioembolization. Semin Liver Dis [Internet]. 2014;34:435–43. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0034-1394142)
Sangro B, Salem R. Transarterial Chemoembolization and Radioembolization. Semin Liver Dis [Internet]. 2014;34:435–43. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0034-1394142Sangro B, Salem R. Transarterial Chemoembolization and Radioembolization. Semin Liver Dis [Internet]. 2014;34:435–43. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0034-1394142, Sangro B, Salem R. Transarterial Chemoembolization and Radioembolization. Semin Liver Dis [Internet]. 2014;34:435–43. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0034-1394142
T. Hong, J. Wo, B. Yeap, E. Ben-Josef, E. McDonnell, L. Blaszkowsky, E. Kwak, Jill Allen, Jeffrey Clark, L. Goyal, Janet Murphy, M. Javle, J. Wolfgang, L. Drapek, R. Arellano, H. Mamon, J. Mullen, Sam Yoon, K. Tanabe, C. Ferrone, D. Ryan, T. Delaney, C. Crane, A. Zhu (2016)
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 5
(Oh JH, Sinn DH, Choi G-S, Kim JM, Joh J-W, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res [Internet]. 2020;99:238. https://astr.or.kr/DOIx.php?id=10.4174/astr.2020.99.4.238)
Oh JH, Sinn DH, Choi G-S, Kim JM, Joh J-W, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res [Internet]. 2020;99:238. https://astr.or.kr/DOIx.php?id=10.4174/astr.2020.99.4.238Oh JH, Sinn DH, Choi G-S, Kim JM, Joh J-W, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res [Internet]. 2020;99:238. https://astr.or.kr/DOIx.php?id=10.4174/astr.2020.99.4.238, Oh JH, Sinn DH, Choi G-S, Kim JM, Joh J-W, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res [Internet]. 2020;99:238. https://astr.or.kr/DOIx.php?id=10.4174/astr.2020.99.4.238
(Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol [Internet]. 2019;16:589–604. http://www.nature.com/articles/s41575-019-0186-y)
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol [Internet]. 2019;16:589–604. http://www.nature.com/articles/s41575-019-0186-yYang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol [Internet]. 2019;16:589–604. http://www.nature.com/articles/s41575-019-0186-y, Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol [Internet]. 2019;16:589–604. http://www.nature.com/articles/s41575-019-0186-y
(Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, et al. Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis. Am J Roentgenol [Internet]. 2020;AJR.20.24117. https://www.ajronline.org/doi/10.2214/AJR.20.24117)
Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, et al. Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis. Am J Roentgenol [Internet]. 2020;AJR.20.24117. https://www.ajronline.org/doi/10.2214/AJR.20.24117Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, et al. Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis. Am J Roentgenol [Internet]. 2020;AJR.20.24117. https://www.ajronline.org/doi/10.2214/AJR.20.24117, Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, et al. Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis. Am J Roentgenol [Internet]. 2020;AJR.20.24117. https://www.ajronline.org/doi/10.2214/AJR.20.24117
(Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster DM, et al. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction? Cardiovasc Intervent Radiol [Internet]. 2021;44:254–60. http://link.springer.com/10.1007/s00270-020-02638-8)
Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster DM, et al. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction? Cardiovasc Intervent Radiol [Internet]. 2021;44:254–60. http://link.springer.com/10.1007/s00270-020-02638-8Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster DM, et al. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction? Cardiovasc Intervent Radiol [Internet]. 2021;44:254–60. http://link.springer.com/10.1007/s00270-020-02638-8, Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster DM, et al. Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction? Cardiovasc Intervent Radiol [Internet]. 2021;44:254–60. http://link.springer.com/10.1007/s00270-020-02638-8
(Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: A systematic review. Hepatol Int [Internet]. 2008;2:17–30. http://link.springer.com/10.1007/s12072-007-9038-x)
Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: A systematic review. Hepatol Int [Internet]. 2008;2:17–30. http://link.springer.com/10.1007/s12072-007-9038-xTateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: A systematic review. Hepatol Int [Internet]. 2008;2:17–30. http://link.springer.com/10.1007/s12072-007-9038-x, Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: A systematic review. Hepatol Int [Internet]. 2008;2:17–30. http://link.springer.com/10.1007/s12072-007-9038-x
S. Ibrahim, R. Lewandowski, Kent Sato, V. Gates, L. Kulik, M. Mulcahy, R. Ryu, R. Omary, R. Salem (2008)
Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.World journal of gastroenterology, 14 11
(Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Moon YM, et al. Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma. Oncology [Internet]. 2009;76:1–9. https://www.karger.com/Article/FullText/173735)
Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Moon YM, et al. Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma. Oncology [Internet]. 2009;76:1–9. https://www.karger.com/Article/FullText/173735Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Moon YM, et al. Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma. Oncology [Internet]. 2009;76:1–9. https://www.karger.com/Article/FullText/173735, Sohn JH, Choi HJ, Lee JT, Lee JD, Kim JH, Moon YM, et al. Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular Carcinoma. Oncology [Internet]. 2009;76:1–9. https://www.karger.com/Article/FullText/173735
P. Galle, A. Forner, J. Llovet, V. Mazzaferro, F. Piscaglia, J. Raoul, P. Schirmacher, V. Vilgrain (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.Journal of hepatology, 69 1
Kostas Delaunay, J. Edeline, Y. Rolland, N. Lepareur, S. Laffont, X. Palard, C. Bouvry, S. Sourd, M. Pracht, V. Ardisson, N. Noiret, É. Bellissant, E. Garin (2019)
Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolizationEuropean Journal of Nuclear Medicine and Molecular Imaging, 46
Te-Chun Hsieh, Yu‐Chin Wu, Shung‐Shung Sun, Kuo‐Yang Yen, C. Kao (2016)
Treating hepatocellular carcinoma with 90Y-bearing microspheres: a reviewBioMedicine, 6
(Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. J Nucl Med [Internet]. 2012;53:1633–51. http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.112.105148)
Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. J Nucl Med [Internet]. 2012;53:1633–51. http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.112.105148Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. J Nucl Med [Internet]. 2012;53:1633–51. http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.112.105148, Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. J Nucl Med [Internet]. 2012;53:1633–51. http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.112.105148
(Raoul JI, Bretagne JF, Caucanas JP, Pariente EA, Boyer J, Paris JC, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer [Internet]. 1992;69:346–52. https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19920115)69:2%3C346::AID-CNCR2820690212%3E3.0.CO;2-E)
Raoul JI, Bretagne JF, Caucanas JP, Pariente EA, Boyer J, Paris JC, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer [Internet]. 1992;69:346–52. https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19920115)69:2%3C346::AID-CNCR2820690212%3E3.0.CO;2-ERaoul JI, Bretagne JF, Caucanas JP, Pariente EA, Boyer J, Paris JC, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer [Internet]. 1992;69:346–52. https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19920115)69:2%3C346::AID-CNCR2820690212%3E3.0.CO;2-E, Raoul JI, Bretagne JF, Caucanas JP, Pariente EA, Boyer J, Paris JC, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer [Internet]. 1992;69:346–52. https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19920115)69:2%3C346::AID-CNCR2820690212%3E3.0.CO;2-E
Luhua Wang, Jiade Lu, W. Yin, J. Lang (2017)
Perspectives on Patient Access to Radiation Oncology Facilities and Services in Mainland China.Seminars in radiation oncology, 27 2
L. Uccelli, M. Pasquali, A. Boschi, M. Giganti, A. Duatti (2011)
Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma.Nuclear medicine and biology, 38 2
Uttara Saran, B. Humar, P. Kolly, J. Dufour (2016)
Hepatocellular carcinoma and lifestyles.Journal of hepatology, 64 1
(Yoo GS, Yu J Il, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol [Internet]. 2018;24:3090–100. http://www.wjgnet.com/1007-9327/full/v24/i28/3090.htm)
Yoo GS, Yu J Il, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol [Internet]. 2018;24:3090–100. http://www.wjgnet.com/1007-9327/full/v24/i28/3090.htmYoo GS, Yu J Il, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol [Internet]. 2018;24:3090–100. http://www.wjgnet.com/1007-9327/full/v24/i28/3090.htm, Yoo GS, Yu J Il, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol [Internet]. 2018;24:3090–100. http://www.wjgnet.com/1007-9327/full/v24/i28/3090.htm
E. Silberstein, A. Alavi, H. Balon, S. Clarke, C. Divgi, M. Gelfand, S. Goldsmith, H. Jadvar, C. Marcus, W. Martin, J. Parker, H. Royal, S. Sarkar, M. Stabin, A. Waxman (2012)
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0*The Journal of Nuclear Medicine, 53
G. Yoo, J. Yu, H. Park (2018)
Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives.World journal of gastroenterology, 24 28
S. Yoganathan, K. Das, A. Agarwal, Shaleen Kumar (2017)
Magnitude, Impact, and Management of Respiration-induced Target Motion in Radiotherapy Treatment: A Comprehensive ReviewJournal of Medical Physics, 42
W. Lau, S. Ho, T. Leung, M. Chan, R. Ho, P. Johnson, A. Li (1998)
Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.International journal of radiation oncology, biology, physics, 40 3
(Jung I-H, Yoon SM, Kwak J, Park J-H, Song SY, Lee S-W, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget [Internet]. 2017;8:15182–92. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.14858)
Jung I-H, Yoon SM, Kwak J, Park J-H, Song SY, Lee S-W, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget [Internet]. 2017;8:15182–92. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.14858Jung I-H, Yoon SM, Kwak J, Park J-H, Song SY, Lee S-W, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget [Internet]. 2017;8:15182–92. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.14858, Jung I-H, Yoon SM, Kwak J, Park J-H, Song SY, Lee S-W, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget [Internet]. 2017;8:15182–92. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.14858
Li Zhang, Jia Ding, Hui-Yan Li, Zhong-Hua Wang, Jian Wu (2020)
Immunotherapy for advanced hepatocellular carcinoma, where are we?Biochimica et biophysica acta. Reviews on cancer
A. Haug (2017)
Imaging of primary liver tumors with positron-emission tomography.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 61 3
D. Manas, J. Bell, S. Mealing, H. Davies, H. Baker, H. Holmes, R. Hubner (2020)
The cost-effectiveness of therasphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Jiao D, Li Y, Yang F, Han D, Wu J, Shi S, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol [Internet]. 2019;10:e00041. https://journals.lww.com/01720094-201905000-00006)
Jiao D, Li Y, Yang F, Han D, Wu J, Shi S, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol [Internet]. 2019;10:e00041. https://journals.lww.com/01720094-201905000-00006Jiao D, Li Y, Yang F, Han D, Wu J, Shi S, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol [Internet]. 2019;10:e00041. https://journals.lww.com/01720094-201905000-00006, Jiao D, Li Y, Yang F, Han D, Wu J, Shi S, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin Transl Gastroenterol [Internet]. 2019;10:e00041. https://journals.lww.com/01720094-201905000-00006
Ding‐Shinn Chen, J. Sung (1977)
Serum alphafetoprotein in hepatocellular carcinomaCancer, 40
Kerui Xu, S. Watanabe-Galloway, F. Rochling, Jianjun Zhang, P. Farazi, Hongyan Peng, Hongmei Wang, Jiangtao Luo (2017)
Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients.Annals of global health, 83 2
(2017)
on Organ Donation and Transplantation Activities: Executive Summary 2017
(Lokesh KN, Chaudhuri T, Lakshmaiah KC, Govind Babu K, Dasappa L, Jacob LA, et al. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases. Indian J Cancer [Internet]. 2017;54:526–9. http://www.indianjcancer.com/text.asp?2017/54/3/526/233153)
Lokesh KN, Chaudhuri T, Lakshmaiah KC, Govind Babu K, Dasappa L, Jacob LA, et al. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases. Indian J Cancer [Internet]. 2017;54:526–9. http://www.indianjcancer.com/text.asp?2017/54/3/526/233153Lokesh KN, Chaudhuri T, Lakshmaiah KC, Govind Babu K, Dasappa L, Jacob LA, et al. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases. Indian J Cancer [Internet]. 2017;54:526–9. http://www.indianjcancer.com/text.asp?2017/54/3/526/233153, Lokesh KN, Chaudhuri T, Lakshmaiah KC, Govind Babu K, Dasappa L, Jacob LA, et al. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases. Indian J Cancer [Internet]. 2017;54:526–9. http://www.indianjcancer.com/text.asp?2017/54/3/526/233153
Y. Tolkach, D. Goltz, A. Kremer, H. Ahmadzadehfar, Dominik Bergheim, M. Essler, M. Lam, B. Keizer, H. Fischer, G. Kristiansen (2019)
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imagingOncotarget, 10
Si-yuan Zhang, G. Zhu, Gong Li, Yibao Zhang, J. Geng (2016)
Application of stereotactic body radiation therapy to cancer liver metastasis.Cancer letters, 379 2
(Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. Acta Oncol (Madr) [Internet]. 2014;53:399–404. http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.820342)
Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. Acta Oncol (Madr) [Internet]. 2014;53:399–404. http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.820342Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. Acta Oncol (Madr) [Internet]. 2014;53:399–404. http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.820342, Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. Acta Oncol (Madr) [Internet]. 2014;53:399–404. http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.820342
(Yoganathan S, Maria Das K, Agarwal A, Kumar S. Magnitude, impact, and management of respiration-induced target motion in radiotherapy treatment: A comprehensive review. J Med Phys [Internet]. 2017;42:101. http://www.jmp.org.in/text.asp?2017/42/3/101/214491)
Yoganathan S, Maria Das K, Agarwal A, Kumar S. Magnitude, impact, and management of respiration-induced target motion in radiotherapy treatment: A comprehensive review. J Med Phys [Internet]. 2017;42:101. http://www.jmp.org.in/text.asp?2017/42/3/101/214491Yoganathan S, Maria Das K, Agarwal A, Kumar S. Magnitude, impact, and management of respiration-induced target motion in radiotherapy treatment: A comprehensive review. J Med Phys [Internet]. 2017;42:101. http://www.jmp.org.in/text.asp?2017/42/3/101/214491, Yoganathan S, Maria Das K, Agarwal A, Kumar S. Magnitude, impact, and management of respiration-induced target motion in radiotherapy treatment: A comprehensive review. J Med Phys [Internet]. 2017;42:101. http://www.jmp.org.in/text.asp?2017/42/3/101/214491
(Chan SL, Chan AWH, Yu SCH. Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. 2017. p. 623–35. http://link.springer.com/10.1007/978-94-007-7675-3_41)
Chan SL, Chan AWH, Yu SCH. Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. 2017. p. 623–35. http://link.springer.com/10.1007/978-94-007-7675-3_41Chan SL, Chan AWH, Yu SCH. Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. 2017. p. 623–35. http://link.springer.com/10.1007/978-94-007-7675-3_41, Chan SL, Chan AWH, Yu SCH. Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. 2017. p. 623–35. http://link.springer.com/10.1007/978-94-007-7675-3_41
Hanyu Jiang, Jie Chen, C. Xia, Likun Cao, Ting Duan, B. Song (2018)
Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosisWorld Journal of Gastroenterology, 24
Tae Kim, Joong-Won Park, B. Kim, Hyun-Jee Kim, S. Moon, Sang Kim, S. Woo, Y. Koh, Woojin Lee, D. Kim, Chang‐Min Kim (2019)
Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?Cancers, 11
N. Kokudo, K. Hasegawa, M. Akahane, H. Igaki, N. Izumi, T. Ichida, S. Uemoto, S. Kaneko, S. Kawasaki, Y. Ku, M. Kudo, S. Kubo, T. Takayama, R. Tateishi, T. Fukuda, O. Matsui, Y. Matsuyama, T. Murakami, S. Arii, M. Okazaki, M. Makuuchi (2015)
Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines)Hepatology Research, 45
(Chen CP. Role of radiotherapy in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol [Internet]. 2019;7:183–90. http://www.xiahepublishing.com/2310-8819/ArticleFullText.aspx?sid=2&id=10.14218%2FJCTH.2018.00060)
Chen CP. Role of radiotherapy in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol [Internet]. 2019;7:183–90. http://www.xiahepublishing.com/2310-8819/ArticleFullText.aspx?sid=2&id=10.14218%2FJCTH.2018.00060Chen CP. Role of radiotherapy in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol [Internet]. 2019;7:183–90. http://www.xiahepublishing.com/2310-8819/ArticleFullText.aspx?sid=2&id=10.14218%2FJCTH.2018.00060, Chen CP. Role of radiotherapy in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol [Internet]. 2019;7:183–90. http://www.xiahepublishing.com/2310-8819/ArticleFullText.aspx?sid=2&id=10.14218%2FJCTH.2018.00060
K. Reiss, Shun Yu, R. Mamtani, Rajni Mehta, Kathryn D’Addeo, E. Wileyto, T. Taddei, D. Kaplan (2017)
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 31
R. Price, S. Apisarnthanarax, S. Schaub, Matthew Nyflot, T. Chapman, Manuela Matesan, H. Vesselle, S. Bowen (2018)
Regional Radiation Dose-Response Modeling of Functional Liver in Hepatocellular Carcinoma Patients With Longitudinal Sulfur Colloid SPECT/CT: A Proof of Concept.International journal of radiation oncology, biology, physics, 102 4
nature publishing group ORIGINAL CONTRIBUTIONS 569 CME Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors LIVER
S. Chan, A. Chan, Simon Yu (2016)
Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response
(Bal CS, Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol [Internet]. 2008;29:62–70. http://www.ncbi.nlm.nih.gov/pubmed/18972764)
Bal CS, Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol [Internet]. 2008;29:62–70. http://www.ncbi.nlm.nih.gov/pubmed/18972764Bal CS, Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol [Internet]. 2008;29:62–70. http://www.ncbi.nlm.nih.gov/pubmed/18972764, Bal CS, Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol [Internet]. 2008;29:62–70. http://www.ncbi.nlm.nih.gov/pubmed/18972764
Changqing Zhao, M. Nguyen (2016)
Hepatocellular Carcinoma Screening and Surveillance: Practice Guidelines and Real-Life PracticeJournal of Clinical Gastroenterology, 50
I. Jung, S. Yoon, J. Kwak, Jin-hong Park, S. Song, Sang‐wook Lee, S. Ahn, E. Choi, Jong Kim (2017)
High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinomaOncotarget, 8
(Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet [Internet]. 2018;391:1163–73. https://linkinghub.elsevier.com/retrieve/pii/S0140673618302071)
Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet [Internet]. 2018;391:1163–73. https://linkinghub.elsevier.com/retrieve/pii/S0140673618302071Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet [Internet]. 2018;391:1163–73. https://linkinghub.elsevier.com/retrieve/pii/S0140673618302071, Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet [Internet]. 2018;391:1163–73. https://linkinghub.elsevier.com/retrieve/pii/S0140673618302071
(Levy I, Sherman M, The Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut [Internet]. 2002;50:881–5. https://gut.bmj.com/lookup/doi/10.1136/gut.50.6.881)
Levy I, Sherman M, The Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut [Internet]. 2002;50:881–5. https://gut.bmj.com/lookup/doi/10.1136/gut.50.6.881Levy I, Sherman M, The Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut [Internet]. 2002;50:881–5. https://gut.bmj.com/lookup/doi/10.1136/gut.50.6.881, Levy I, Sherman M, The Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut [Internet]. 2002;50:881–5. https://gut.bmj.com/lookup/doi/10.1136/gut.50.6.881
(Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging [Internet]. 2011;38:1393–406. http://link.springer.com/10.1007/s00259-011-1812-2)
Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging [Internet]. 2011;38:1393–406. http://link.springer.com/10.1007/s00259-011-1812-2Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging [Internet]. 2011;38:1393–406. http://link.springer.com/10.1007/s00259-011-1812-2, Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging [Internet]. 2011;38:1393–406. http://link.springer.com/10.1007/s00259-011-1812-2
(Mallia MB, Chirayil V, Dash A. Improved freeze-dried kit for the preparation of 188 ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma. Appl Radiat Isot [Internet]. 2018;137:147–53. https://linkinghub.elsevier.com/retrieve/pii/S0969804317312290)
Mallia MB, Chirayil V, Dash A. Improved freeze-dried kit for the preparation of 188 ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma. Appl Radiat Isot [Internet]. 2018;137:147–53. https://linkinghub.elsevier.com/retrieve/pii/S0969804317312290Mallia MB, Chirayil V, Dash A. Improved freeze-dried kit for the preparation of 188 ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma. Appl Radiat Isot [Internet]. 2018;137:147–53. https://linkinghub.elsevier.com/retrieve/pii/S0969804317312290, Mallia MB, Chirayil V, Dash A. Improved freeze-dried kit for the preparation of 188 ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma. Appl Radiat Isot [Internet]. 2018;137:147–53. https://linkinghub.elsevier.com/retrieve/pii/S0969804317312290
(Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol [Internet]. 2016;22:353. http://www.saudijgastro.com/text.asp?2016/22/5/353/191139)
Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol [Internet]. 2016;22:353. http://www.saudijgastro.com/text.asp?2016/22/5/353/191139Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol [Internet]. 2016;22:353. http://www.saudijgastro.com/text.asp?2016/22/5/353/191139, Jia Z, Jiang G, Tian F, Zhu C, Qin X. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Saudi J Gastroenterol [Internet]. 2016;22:353. http://www.saudijgastro.com/text.asp?2016/22/5/353/191139
M. Mizumoto, Y. Oshiro, T. Okumura, N. Fukumitsu, H. Numajiri, K. Ohnishi, T. Aihara, H. Ishikawa, K. Tsuboi, H. Sakurai (2016)
Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience.International journal of particle therapy, 2 4
(Schwarze V, Marschner C, Völckers W, De Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; A retrospective single-center analysis of 292 patients. Hiebl B, Krüger-Genge A, Jung F, editors. Clin Hemorheol Microcirc [Internet]. 2020;76:155–60. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CH-209213)
Schwarze V, Marschner C, Völckers W, De Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; A retrospective single-center analysis of 292 patients. Hiebl B, Krüger-Genge A, Jung F, editors. Clin Hemorheol Microcirc [Internet]. 2020;76:155–60. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CH-209213Schwarze V, Marschner C, Völckers W, De Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; A retrospective single-center analysis of 292 patients. Hiebl B, Krüger-Genge A, Jung F, editors. Clin Hemorheol Microcirc [Internet]. 2020;76:155–60. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CH-209213, Schwarze V, Marschner C, Völckers W, De Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; A retrospective single-center analysis of 292 patients. Hiebl B, Krüger-Genge A, Jung F, editors. Clin Hemorheol Microcirc [Internet]. 2020;76:155–60. https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CH-209213
(Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr [Internet]. 2020;9:452–63. http://www.ncbi.nlm.nih.gov/pubmed/32832496)
Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr [Internet]. 2020;9:452–63. http://www.ncbi.nlm.nih.gov/pubmed/32832496Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr [Internet]. 2020;9:452–63. http://www.ncbi.nlm.nih.gov/pubmed/32832496, Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr [Internet]. 2020;9:452–63. http://www.ncbi.nlm.nih.gov/pubmed/32832496
I. Levy, M. Sherman (2002)
Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in TorontoGut, 50
C. Frenette, A. Isaacson, I. Bargellini, S. Saab, A. Singal (2019)
A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at RiskMayo Clinic Proceedings: Innovations, Quality & Outcomes, 3
(Mantravadi R V, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology [Internet]. 1982;142:783–6. http://pubs.rsna.org/doi/10.1148/radiology.142.3.7063703)
Mantravadi R V, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology [Internet]. 1982;142:783–6. http://pubs.rsna.org/doi/10.1148/radiology.142.3.7063703Mantravadi R V, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology [Internet]. 1982;142:783–6. http://pubs.rsna.org/doi/10.1148/radiology.142.3.7063703, Mantravadi R V, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology [Internet]. 1982;142:783–6. http://pubs.rsna.org/doi/10.1148/radiology.142.3.7063703
S. Lohar, S. Jadhav, Rubel Chakravarty, S. Chakraborty, Haladhar Sarma, A. Dash (2020)
A kit based methodology for convenient formulation of 166Ho-Chitosan complex for treatment of liver cancer.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 161
(Hsieh T-C, Wu Y-C, Sun S-S, Yen K-Y, Kao C-H. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. BioMedicine [Internet]. 2016;6:19. http://www.globalsciencejournals.com/article/10.7603/s40681-016-0019-z)
Hsieh T-C, Wu Y-C, Sun S-S, Yen K-Y, Kao C-H. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. BioMedicine [Internet]. 2016;6:19. http://www.globalsciencejournals.com/article/10.7603/s40681-016-0019-zHsieh T-C, Wu Y-C, Sun S-S, Yen K-Y, Kao C-H. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. BioMedicine [Internet]. 2016;6:19. http://www.globalsciencejournals.com/article/10.7603/s40681-016-0019-z, Hsieh T-C, Wu Y-C, Sun S-S, Yen K-Y, Kao C-H. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. BioMedicine [Internet]. 2016;6:19. http://www.globalsciencejournals.com/article/10.7603/s40681-016-0019-z
Y. Ko, Joohwan Bae, D. Sinn, G. Gwak, W. Kang, Y. Paik, M. Choi, J. Lee, K. Koh, S. Paik (2017)
[The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 69 4
(Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology [Internet]. 2018;154:1706–1718.e1. https://linkinghub.elsevier.com/retrieve/pii/S0016508518301550)
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology [Internet]. 2018;154:1706–1718.e1. https://linkinghub.elsevier.com/retrieve/pii/S0016508518301550Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology [Internet]. 2018;154:1706–1718.e1. https://linkinghub.elsevier.com/retrieve/pii/S0016508518301550, Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology [Internet]. 2018;154:1706–1718.e1. https://linkinghub.elsevier.com/retrieve/pii/S0016508518301550
H. El‐Serag, J. Marrero, L. Rudolph, K. Reddy (2008)
Diagnosis and treatment of hepatocellular carcinoma.Gastroenterology, 134 6
M. Omata, A. Cheng, N. Kokudo, M. Kudo, J. Lee, J. Jia, R. Tateishi, K. Han, Y. Chawla, S. Shiina, W. Jafri, D. Payawal, T. Ohki, S. Ogasawara, Pei‐Jer Chen, C. Lesmana, L. Lesmana, R. Gani, S. Obi, A. Dokmeci, S. Sarin (2017)
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatology International, 11
(Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol [Internet]. 2013;21:170–6. https://journals.lww.com/00129039-201303000-00011)
Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol [Internet]. 2013;21:170–6. https://journals.lww.com/00129039-201303000-00011Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol [Internet]. 2013;21:170–6. https://journals.lww.com/00129039-201303000-00011, Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol [Internet]. 2013;21:170–6. https://journals.lww.com/00129039-201303000-00011
L. Mak, V. Cruz-Ramon, Paulina Chinchilla-López, H. Torres, N. Loconte, J. Rice, L. Foxhall, E. Sturgis, Janette Merrill, H. Bailey, N. Méndez-Sánchez, M. Yuen, J. Hwang (2018)
Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 38
(Chakravarty R, Dash A. Nano Structured Metal Oxides as Potential Sorbents for 188 W/188 Re Generator: A Comparative Study. Sep Sci Technol [Internet]. 2013;48:607–16. http://www.tandfonline.com/doi/abs/10.1080/01496395.2012.713433)
Chakravarty R, Dash A. Nano Structured Metal Oxides as Potential Sorbents for 188 W/188 Re Generator: A Comparative Study. Sep Sci Technol [Internet]. 2013;48:607–16. http://www.tandfonline.com/doi/abs/10.1080/01496395.2012.713433Chakravarty R, Dash A. Nano Structured Metal Oxides as Potential Sorbents for 188 W/188 Re Generator: A Comparative Study. Sep Sci Technol [Internet]. 2013;48:607–16. http://www.tandfonline.com/doi/abs/10.1080/01496395.2012.713433, Chakravarty R, Dash A. Nano Structured Metal Oxides as Potential Sorbents for 188 W/188 Re Generator: A Comparative Study. Sep Sci Technol [Internet]. 2013;48:607–16. http://www.tandfonline.com/doi/abs/10.1080/01496395.2012.713433
J. Heimbach, L. Kulik, R. Finn, C. Sirlin, M. Abecassis, L. Roberts, A. Zhu, M. Murad, J. Marrero (2018)
AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 67
(Soldera J, Balbinot SS, Balbinot RA, Cavalcanti AG. Diagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer Protocol. Clin Med Insights Gastroenterol [Internet]. 2016;9:CGast.S30190. http://journals.sagepub.com/doi/10.4137/CGast.S30190)
Soldera J, Balbinot SS, Balbinot RA, Cavalcanti AG. Diagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer Protocol. Clin Med Insights Gastroenterol [Internet]. 2016;9:CGast.S30190. http://journals.sagepub.com/doi/10.4137/CGast.S30190Soldera J, Balbinot SS, Balbinot RA, Cavalcanti AG. Diagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer Protocol. Clin Med Insights Gastroenterol [Internet]. 2016;9:CGast.S30190. http://journals.sagepub.com/doi/10.4137/CGast.S30190, Soldera J, Balbinot SS, Balbinot RA, Cavalcanti AG. Diagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer Protocol. Clin Med Insights Gastroenterol [Internet]. 2016;9:CGast.S30190. http://journals.sagepub.com/doi/10.4137/CGast.S30190
(Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol [Internet]. 2012;107:569–77. https://journals.lww.com/00000434-201204000-00016)
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol [Internet]. 2012;107:569–77. https://journals.lww.com/00000434-201204000-00016Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol [Internet]. 2012;107:569–77. https://journals.lww.com/00000434-201204000-00016, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. Am J Gastroenterol [Internet]. 2012;107:569–77. https://journals.lww.com/00000434-201204000-00016
(Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol [Internet]. 1998;40:583–92. https://linkinghub.elsevier.com/retrieve/pii/S0360301697008183)
Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol [Internet]. 1998;40:583–92. https://linkinghub.elsevier.com/retrieve/pii/S0360301697008183Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol [Internet]. 1998;40:583–92. https://linkinghub.elsevier.com/retrieve/pii/S0360301697008183, Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol [Internet]. 1998;40:583–92. https://linkinghub.elsevier.com/retrieve/pii/S0360301697008183
(Uccelli L, Pasquali M, Boschi A, Giganti M, Duatti A. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma. Nucl Med Biol [Internet]. 2011;38:207–13. https://linkinghub.elsevier.com/retrieve/pii/S096980511000418X)
Uccelli L, Pasquali M, Boschi A, Giganti M, Duatti A. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma. Nucl Med Biol [Internet]. 2011;38:207–13. https://linkinghub.elsevier.com/retrieve/pii/S096980511000418XUccelli L, Pasquali M, Boschi A, Giganti M, Duatti A. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma. Nucl Med Biol [Internet]. 2011;38:207–13. https://linkinghub.elsevier.com/retrieve/pii/S096980511000418X, Uccelli L, Pasquali M, Boschi A, Giganti M, Duatti A. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma. Nucl Med Biol [Internet]. 2011;38:207–13. https://linkinghub.elsevier.com/retrieve/pii/S096980511000418X
N. Horvat, S. Monti, Brunna Oliveira, C. Rocha, R. Giancipoli, L. Mannelli (2018)
State of The Art in Magnetic Resonance Imaging of Hepatocellular CarcinomaRadiology and Oncology, 52
(Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther [Internet]. 2009;30:37–47. http://doi.wiley.com/10.1111/j.1365-2036.2009.04014.x)
Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther [Internet]. 2009;30:37–47. http://doi.wiley.com/10.1111/j.1365-2036.2009.04014.xSingal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther [Internet]. 2009;30:37–47. http://doi.wiley.com/10.1111/j.1365-2036.2009.04014.x, Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, et al. Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther [Internet]. 2009;30:37–47. http://doi.wiley.com/10.1111/j.1365-2036.2009.04014.x
A. Mukherjee, Suresh Subramanian, R. Ambade, B. Avhad, Ashutosh Dash, A. Korde (2017)
Development of Semiautomated Module for Preparation of 131I Labeled Lipiodol for Liver Cancer Therapy.Cancer biotherapy & radiopharmaceuticals, 32 1
(Ko YS, Bae JH, Sinn DH, Gwak GY, Kang W, Paik YH, et al. The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population. Korean J Gastroenterol [Internet]. 2017;69:232–8. https://synapse.koreamed.org/DOIx.php?id=10.4166/kjg.2017.69.4.232)
Ko YS, Bae JH, Sinn DH, Gwak GY, Kang W, Paik YH, et al. The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population. Korean J Gastroenterol [Internet]. 2017;69:232–8. https://synapse.koreamed.org/DOIx.php?id=10.4166/kjg.2017.69.4.232Ko YS, Bae JH, Sinn DH, Gwak GY, Kang W, Paik YH, et al. The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population. Korean J Gastroenterol [Internet]. 2017;69:232–8. https://synapse.koreamed.org/DOIx.php?id=10.4166/kjg.2017.69.4.232, Ko YS, Bae JH, Sinn DH, Gwak GY, Kang W, Paik YH, et al. The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population. Korean J Gastroenterol [Internet]. 2017;69:232–8. https://synapse.koreamed.org/DOIx.php?id=10.4166/kjg.2017.69.4.232
(Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. Hpb [Internet]. 2005;7:35–41. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15308418)
Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. Hpb [Internet]. 2005;7:35–41. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15308418Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. Hpb [Internet]. 2005;7:35–41. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15308418, Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. Hpb [Internet]. 2005;7:35–41. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15308418
K. Omagari, K. Ohba, Yoshiko Kadokawa, H. Hazama, Jun‐ichi Masuda, H. Kinoshita, I. Matsuo, K. Ohnita, Y. Mizuta, K. Hayashida, S. Kohno (2006)
Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma.Hepatology research : the official journal of the Japan Society of Hepatology, 34 4
Ajay Kumar, D. Srivastava, T. Chau, H. Long, C. Bal, P. Chandra, L. Chien, N. Hoa, S. Thulkar, Sanjay Sharma, Le Tam, Truong Xuan, N. Canh, G. Pant, G. Bandopadhyaya (2007)
Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.Radiology, 243 2
G. Céfaro, N. Cellini, L. Basilico (1990)
Role of radiotherapy in the treatment of hepatocellular carcinoma.Rays, 15 3
Rubel Chakravarty, A. Dash (2013)
Nano Structured Metal Oxides as Potential Sorbents for 188W/188Re Generator: A Comparative StudySeparation Science and Technology, 48
(Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer [Internet]. 2017;6:34–43. https://www.karger.com/Article/FullText/449346)
Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer [Internet]. 2017;6:34–43. https://www.karger.com/Article/FullText/449346Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer [Internet]. 2017;6:34–43. https://www.karger.com/Article/FullText/449346, Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, et al. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer [Internet]. 2017;6:34–43. https://www.karger.com/Article/FullText/449346
(Cheung TT-T, Kwok PC-H, Chan S, Cheung C-C, Lee A-S, Lee V, et al. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer [Internet]. 2018;7:40–54. https://www.karger.com/Article/FullText/485984)
Cheung TT-T, Kwok PC-H, Chan S, Cheung C-C, Lee A-S, Lee V, et al. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer [Internet]. 2018;7:40–54. https://www.karger.com/Article/FullText/485984Cheung TT-T, Kwok PC-H, Chan S, Cheung C-C, Lee A-S, Lee V, et al. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer [Internet]. 2018;7:40–54. https://www.karger.com/Article/FullText/485984, Cheung TT-T, Kwok PC-H, Chan S, Cheung C-C, Lee A-S, Lee V, et al. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer [Internet]. 2018;7:40–54. https://www.karger.com/Article/FullText/485984
A. Shinto, Kamaleshwaran Karuppusamy, Radhakrishnan Kurup, A. Pandiyan, A. Jayaraj (2020)
Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinomaNuclear Medicine Communications, 42
J. Kallini, A. Gabr, R. Salem, R. Lewandowski (2016)
Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular CarcinomaAdvances in Therapy, 33
N. Nishida, T. Nishimura, T. Kaido, Kosuke Minaga, K. Yamao, K. Kamata, M. Takenaka, Hiroshi Ida, S. Hagiwara, Y. Minami, T. Sakurai, Tomohiro Watanabe, M. Kudo (2018)
Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic ChemotherapyCancers, 10
(Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology [Internet]. 2018;67:358–80. http://doi.wiley.com/10.1002/hep.29086)
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology [Internet]. 2018;67:358–80. http://doi.wiley.com/10.1002/hep.29086Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology [Internet]. 2018;67:358–80. http://doi.wiley.com/10.1002/hep.29086, Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology [Internet]. 2018;67:358–80. http://doi.wiley.com/10.1002/hep.29086
(Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy—a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol [Internet]. 2016;7:433–40. http://jgo.amegroups.com/article/view/5670/6594)
Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy—a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol [Internet]. 2016;7:433–40. http://jgo.amegroups.com/article/view/5670/6594Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy—a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol [Internet]. 2016;7:433–40. http://jgo.amegroups.com/article/view/5670/6594, Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy—a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol [Internet]. 2016;7:433–40. http://jgo.amegroups.com/article/view/5670/6594
A. Facciorusso, G. Serviddio, N. Muscatiello (2016)
Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis.World journal of hepatology, 8 18
(Kim JK, Han K-H, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clin Cancer Res [Internet]. 2006;12:543–8. http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-05-1730)
Kim JK, Han K-H, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clin Cancer Res [Internet]. 2006;12:543–8. http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-05-1730Kim JK, Han K-H, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clin Cancer Res [Internet]. 2006;12:543–8. http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-05-1730, Kim JK, Han K-H, Lee JT, Paik YH, Ahn SH, Lee JD, et al. Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clin Cancer Res [Internet]. 2006;12:543–8. http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-05-1730
(Lewandowski R, Salem R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. Semin Intervent Radiol [Internet]. 2006;23:064–72. http://www.thieme-connect.de/DOI/DOI?10.1055/s-2006-939842)
Lewandowski R, Salem R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. Semin Intervent Radiol [Internet]. 2006;23:064–72. http://www.thieme-connect.de/DOI/DOI?10.1055/s-2006-939842Lewandowski R, Salem R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. Semin Intervent Radiol [Internet]. 2006;23:064–72. http://www.thieme-connect.de/DOI/DOI?10.1055/s-2006-939842, Lewandowski R, Salem R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. Semin Intervent Radiol [Internet]. 2006;23:064–72. http://www.thieme-connect.de/DOI/DOI?10.1055/s-2006-939842
S. Subramanian, U. Pandey, P. Chaudhari, Monica Tyagi, Sanjay Gupta, Geetanjali Singh, A. Dash, G. Samuel, M. Venkatesh (2016)
Preliminary evaluation of indigenous 90Y-labelled microspheres for therapy of hepatocellular carcinomaThe Indian Journal of Medical Research, 143
(Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget [Internet]. 2017;8:25814–29. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.15730)
Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget [Internet]. 2017;8:25814–29. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.15730Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget [Internet]. 2017;8:25814–29. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.15730, Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget [Internet]. 2017;8:25814–29. https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.15730
(El-Serag HB. Hepatocellular Carcinoma. N Engl J Med [Internet]. 2011;365:1118–27. http://www.nejm.org/doi/10.1056/NEJMra1001683)
El-Serag HB. Hepatocellular Carcinoma. N Engl J Med [Internet]. 2011;365:1118–27. http://www.nejm.org/doi/10.1056/NEJMra1001683El-Serag HB. Hepatocellular Carcinoma. N Engl J Med [Internet]. 2011;365:1118–27. http://www.nejm.org/doi/10.1056/NEJMra1001683, El-Serag HB. Hepatocellular Carcinoma. N Engl J Med [Internet]. 2011;365:1118–27. http://www.nejm.org/doi/10.1056/NEJMra1001683
(Saran U, Humar B, Kolly P, Dufour JF. Hepatocellular carcinoma and lifestyles. J Hepatol [Internet]. 2016;64:203–14. https://linkinghub.elsevier.com/retrieve/pii/S0168827815006005)
Saran U, Humar B, Kolly P, Dufour JF. Hepatocellular carcinoma and lifestyles. J Hepatol [Internet]. 2016;64:203–14. https://linkinghub.elsevier.com/retrieve/pii/S0168827815006005Saran U, Humar B, Kolly P, Dufour JF. Hepatocellular carcinoma and lifestyles. J Hepatol [Internet]. 2016;64:203–14. https://linkinghub.elsevier.com/retrieve/pii/S0168827815006005, Saran U, Humar B, Kolly P, Dufour JF. Hepatocellular carcinoma and lifestyles. J Hepatol [Internet]. 2016;64:203–14. https://linkinghub.elsevier.com/retrieve/pii/S0168827815006005
J. Sohn, H. Choi, Jong Lee, Jong Lee, J. Kim, Y. Moon, K. Park, K. Park, Eunhee Kim, N. Yoo (2008)
Phase II Study of Transarterial Holmium-166-Chitosan Complex Treatment in Patients with a Single, Large Hepatocellular CarcinomaOncology, 76
A. Mathew, E. Atenafu, D. Owen, C. Maurino, A. Brade, J. Brierley, R. Dinniwell, John Kim, C. Cho, J. Ringash, R. Wong, K. Cuneo, M. Feng, T. Lawrence, L. Dawson (2020)
Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.European journal of cancer, 134
(Labeur TA, Cieslak KP, Van Gulik TM, Takkenberg RB, Van Der Velden S, Lam MGEH, et al. The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;41:740–9. https://journals.lww.com/10.1097/MNM.0000000000001224)
Labeur TA, Cieslak KP, Van Gulik TM, Takkenberg RB, Van Der Velden S, Lam MGEH, et al. The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;41:740–9. https://journals.lww.com/10.1097/MNM.0000000000001224Labeur TA, Cieslak KP, Van Gulik TM, Takkenberg RB, Van Der Velden S, Lam MGEH, et al. The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;41:740–9. https://journals.lww.com/10.1097/MNM.0000000000001224, Labeur TA, Cieslak KP, Van Gulik TM, Takkenberg RB, Van Der Velden S, Lam MGEH, et al. The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;41:740–9. https://journals.lww.com/10.1097/MNM.0000000000001224
Mikhail Kesler, C. Levine, D. Hershkovitz, E. Mishani, Y. Menachem, H. Lerman, Y. Zohar, O. Shibolet, E. Even-Sapir (2018)
68Ga-Labeled Prostate-Specific Membrane Antigen Is a Novel PET/CT Tracer for Imaging of Hepatocellular Carcinoma: A Prospective Pilot StudyThe Journal of Nuclear Medicine, 60
(2018 Korean liver cancer association–national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol [Internet]. 2019;20:1042–113. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2019.0140)
2018 Korean liver cancer association–national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol [Internet]. 2019;20:1042–113. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2019.01402018 Korean liver cancer association–national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol [Internet]. 2019;20:1042–113. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2019.0140, 2018 Korean liver cancer association–national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol [Internet]. 2019;20:1042–113. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2019.0140
(Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin Nucl Med [Internet]. 2019;49:237–43. https://linkinghub.elsevier.com/retrieve/pii/S0001299819300157)
Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin Nucl Med [Internet]. 2019;49:237–43. https://linkinghub.elsevier.com/retrieve/pii/S0001299819300157Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin Nucl Med [Internet]. 2019;49:237–43. https://linkinghub.elsevier.com/retrieve/pii/S0001299819300157, Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin Nucl Med [Internet]. 2019;49:237–43. https://linkinghub.elsevier.com/retrieve/pii/S0001299819300157
(Sharma Y, Weaver MJ, Ludwig DR, Fowler K, Vachharajani N, Chapman WC, et al. Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. Surg (United States) [Internet]. 2018;163:1002–7. https://linkinghub.elsevier.com/retrieve/pii/S0039606017308048)
Sharma Y, Weaver MJ, Ludwig DR, Fowler K, Vachharajani N, Chapman WC, et al. Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. Surg (United States) [Internet]. 2018;163:1002–7. https://linkinghub.elsevier.com/retrieve/pii/S0039606017308048Sharma Y, Weaver MJ, Ludwig DR, Fowler K, Vachharajani N, Chapman WC, et al. Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. Surg (United States) [Internet]. 2018;163:1002–7. https://linkinghub.elsevier.com/retrieve/pii/S0039606017308048, Sharma Y, Weaver MJ, Ludwig DR, Fowler K, Vachharajani N, Chapman WC, et al. Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection. Surg (United States) [Internet]. 2018;163:1002–7. https://linkinghub.elsevier.com/retrieve/pii/S0039606017308048
Melody Xu, M. Feng (2018)
Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?Seminars in Liver Disease, 39
(Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther [Internet]. 2017;17:911–24. https://www.tandfonline.com/doi/full/10.1080/14737140.2017.1368392)
Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther [Internet]. 2017;17:911–24. https://www.tandfonline.com/doi/full/10.1080/14737140.2017.1368392Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther [Internet]. 2017;17:911–24. https://www.tandfonline.com/doi/full/10.1080/14737140.2017.1368392, Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther [Internet]. 2017;17:911–24. https://www.tandfonline.com/doi/full/10.1080/14737140.2017.1368392
(Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma. Ann Surg [Internet]. 2008;247:43–8. https://journals.lww.com/00000658-200801000-00009)
Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma. Ann Surg [Internet]. 2008;247:43–8. https://journals.lww.com/00000658-200801000-00009Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma. Ann Surg [Internet]. 2008;247:43–8. https://journals.lww.com/00000658-200801000-00009, Lau WY, Lai ECH, Leung TWT, Yu SCH. Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma. Ann Surg [Internet]. 2008;247:43–8. https://journals.lww.com/00000658-200801000-00009
(Shinto AS, Karuppusamy KK, Kurup RER, Pandiyan A, Jayaraj A V. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;Publish Ah. https://journals.lww.com/10.1097/MNM.0000000000001296)
Shinto AS, Karuppusamy KK, Kurup RER, Pandiyan A, Jayaraj A V. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;Publish Ah. https://journals.lww.com/10.1097/MNM.0000000000001296Shinto AS, Karuppusamy KK, Kurup RER, Pandiyan A, Jayaraj A V. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;Publish Ah. https://journals.lww.com/10.1097/MNM.0000000000001296, Shinto AS, Karuppusamy KK, Kurup RER, Pandiyan A, Jayaraj A V. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. Nucl Med Commun [Internet]. 2020;Publish Ah. https://journals.lww.com/10.1097/MNM.0000000000001296
(Subramanian S, Pandey U, Chaudhari P, Tyagi M, Gupta S, Singh G, et al. Preliminary evaluation of indigenous 90Y-labelled microspheres for therapy of hepatocellular carcinoma. Indian J Med Res Suppl. 2016;143.)
Subramanian S, Pandey U, Chaudhari P, Tyagi M, Gupta S, Singh G, et al. Preliminary evaluation of indigenous 90Y-labelled microspheres for therapy of hepatocellular carcinoma. Indian J Med Res Suppl. 2016;143.Subramanian S, Pandey U, Chaudhari P, Tyagi M, Gupta S, Singh G, et al. Preliminary evaluation of indigenous 90Y-labelled microspheres for therapy of hepatocellular carcinoma. Indian J Med Res Suppl. 2016;143., Subramanian S, Pandey U, Chaudhari P, Tyagi M, Gupta S, Singh G, et al. Preliminary evaluation of indigenous 90Y-labelled microspheres for therapy of hepatocellular carcinoma. Indian J Med Res Suppl. 2016;143.
B. Sangro, R. Salem (2014)
Transarterial Chemoembolization and RadioembolizationSeminars in Liver Disease, 34
N. Méndez-Sánchez, E. Ridruejo, A. Mattos, N. Chavez-Tapia, R. Zapata, R. Paraná, R. Mastai, E. Strauss, L. Guevara-Casallas, J. Daruich, A. Gadano, E. Parise, M. Uribe, N. Aguilar-Olivos, L. Dagher, B. Ferraz-Neto, M. Valdés-Sánchez, J. Sánchez-Ávila (2014)
Clinical practice guidelines: Management of Hepatocellular CarcinomaAnnals of Hepatology, 13
(Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, et al. Regional Radiation Dose-Response Modeling of Functional Liver in Hepatocellular Carcinoma Patients With Longitudinal Sulfur Colloid SPECT/CT: A Proof of Concept. Int J Radiat Oncol Biol Phys [Internet]. 2018;102:1349–56. https://linkinghub.elsevier.com/retrieve/pii/S0360301618310083)
Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, et al. Regional Radiation Dose-Response Modeling of Functional Liver in Hepatocellular Carcinoma Patients With Longitudinal Sulfur Colloid SPECT/CT: A Proof of Concept. Int J Radiat Oncol Biol Phys [Internet]. 2018;102:1349–56. https://linkinghub.elsevier.com/retrieve/pii/S0360301618310083Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, et al. Regional Radiation Dose-Response Modeling of Functional Liver in Hepatocellular Carcinoma Patients With Longitudinal Sulfur Colloid SPECT/CT: A Proof of Concept. Int J Radiat Oncol Biol Phys [Internet]. 2018;102:1349–56. https://linkinghub.elsevier.com/retrieve/pii/S0360301618310083, Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, et al. Regional Radiation Dose-Response Modeling of Functional Liver in Hepatocellular Carcinoma Patients With Longitudinal Sulfur Colloid SPECT/CT: A Proof of Concept. Int J Radiat Oncol Biol Phys [Internet]. 2018;102:1349–56. https://linkinghub.elsevier.com/retrieve/pii/S0360301618310083
(Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, et al. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol [Internet]. 2021;47:401–8. https://linkinghub.elsevier.com/retrieve/pii/S0748798320307198)
Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, et al. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol [Internet]. 2021;47:401–8. https://linkinghub.elsevier.com/retrieve/pii/S0748798320307198Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, et al. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol [Internet]. 2021;47:401–8. https://linkinghub.elsevier.com/retrieve/pii/S0748798320307198, Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, et al. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol [Internet]. 2021;47:401–8. https://linkinghub.elsevier.com/retrieve/pii/S0748798320307198
S. Asrani, H. Devarbhavi, J. Eaton, P. Kamath (2019)
Burden of liver diseases in the world.Journal of hepatology, 70 1
S. Qin, E. Kruger, S. Tan, Shuqun Cheng, Nanya Wang, Jun Liang (2018)
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in ChinaCost Effectiveness and Resource Allocation : C/E, 16
(Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol [Internet]. 2016;8:770. http://www.wjgnet.com/1948-5182/full/v8/i18/770.htm)
Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol [Internet]. 2016;8:770. http://www.wjgnet.com/1948-5182/full/v8/i18/770.htmFacciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol [Internet]. 2016;8:770. http://www.wjgnet.com/1948-5182/full/v8/i18/770.htm, Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol [Internet]. 2016;8:770. http://www.wjgnet.com/1948-5182/full/v8/i18/770.htm
O. Oladeru, J. Miccio, Jie Yang, Yaqi Xue, S. Ryu, A. Stessin (2016)
Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma.Journal of gastrointestinal oncology, 7 3
(Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. 68 Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med [Internet]. 2019;60:185–91. http://www.ncbi.nlm.nih.gov/pubmed/30002112)
Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. 68 Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med [Internet]. 2019;60:185–91. http://www.ncbi.nlm.nih.gov/pubmed/30002112Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. 68 Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med [Internet]. 2019;60:185–91. http://www.ncbi.nlm.nih.gov/pubmed/30002112, Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, et al. 68 Ga-labeled prostate-specific membrane antigen is a novel PET/CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med [Internet]. 2019;60:185–91. http://www.ncbi.nlm.nih.gov/pubmed/30002112
(Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol [Internet]. 2018;69:182–236. https://linkinghub.elsevier.com/retrieve/pii/S0168827818302150)
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol [Internet]. 2018;69:182–236. https://linkinghub.elsevier.com/retrieve/pii/S0168827818302150Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol [Internet]. 2018;69:182–236. https://linkinghub.elsevier.com/retrieve/pii/S0168827818302150, Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol [Internet]. 2018;69:182–236. https://linkinghub.elsevier.com/retrieve/pii/S0168827818302150
H. Jia, D. Yan, Q. Xiao, G. Zhang (2019)
Correlations of ultrasonic features with severity of liver cancer and p16 expression in patients with liver cancer.Neoplasma, 66 1
(Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, et al. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. Eur J Nucl Med Mol Imaging [Internet]. 2019;46:1506–17. http://link.springer.com/10.1007/s00259-019-04277-9)
Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, et al. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. Eur J Nucl Med Mol Imaging [Internet]. 2019;46:1506–17. http://link.springer.com/10.1007/s00259-019-04277-9Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, et al. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. Eur J Nucl Med Mol Imaging [Internet]. 2019;46:1506–17. http://link.springer.com/10.1007/s00259-019-04277-9, Delaunay K, Edeline J, Rolland Y, Lepareur N, Laffont S, Palard X, et al. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. Eur J Nucl Med Mol Imaging [Internet]. 2019;46:1506–17. http://link.springer.com/10.1007/s00259-019-04277-9
Dian Jiao, Yu Li, Fa Yang, Donghui Han, Jieheng Wu, Shengjia Shi, F. Tian, Zhangyan Guo, Wenjin Xi, Guodong Li, Aizhi Zhao, A. Yang, Weijun Qin, He Wang, Weihong Wen (2019)
Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular CarcinomaClinical and Translational Gastroenterology, 10
(Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer [Internet]. 2020;134:41–51. https://linkinghub.elsevier.com/retrieve/pii/S0959804920302276)
Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer [Internet]. 2020;134:41–51. https://linkinghub.elsevier.com/retrieve/pii/S0959804920302276Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer [Internet]. 2020;134:41–51. https://linkinghub.elsevier.com/retrieve/pii/S0959804920302276, Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer [Internet]. 2020;134:41–51. https://linkinghub.elsevier.com/retrieve/pii/S0959804920302276
R. Hirsch, Chris Mills, R. Sawhney, S. Sood, Virginia Bird, Gauri Mishra, A. Dev, W. Kemp, J. Lubel, S. Roberts, P. Gow, A. Nicoll (2020)
SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study)Journal of Gastrointestinal Cancer, 52
(Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes [Internet]. 2019;3:302–10. https://linkinghub.elsevier.com/retrieve/pii/S2542454819300487)
Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes [Internet]. 2019;3:302–10. https://linkinghub.elsevier.com/retrieve/pii/S2542454819300487Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes [Internet]. 2019;3:302–10. https://linkinghub.elsevier.com/retrieve/pii/S2542454819300487, Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes [Internet]. 2019;3:302–10. https://linkinghub.elsevier.com/retrieve/pii/S2542454819300487
(Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2019;20:282–96. https://linkinghub.elsevier.com/retrieve/pii/S1470204518309379)
Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2019;20:282–96. https://linkinghub.elsevier.com/retrieve/pii/S1470204518309379Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2019;20:282–96. https://linkinghub.elsevier.com/retrieve/pii/S1470204518309379, Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2019;20:282–96. https://linkinghub.elsevier.com/retrieve/pii/S1470204518309379
(Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol [Internet]. 2010;34:1147–54. http://www.ncbi.nlm.nih.gov/pubmed/20661013)
Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol [Internet]. 2010;34:1147–54. http://www.ncbi.nlm.nih.gov/pubmed/20661013Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol [Internet]. 2010;34:1147–54. http://www.ncbi.nlm.nih.gov/pubmed/20661013, Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol [Internet]. 2010;34:1147–54. http://www.ncbi.nlm.nih.gov/pubmed/20661013
Khairuddin Memon, R. Lewandowski, L. Kulik, A. Riaz, M. Mulcahy, R. Salem (2011)
Radioembolization for primary and metastatic liver cancer.Seminars in radiation oncology, 21 4
Lu Wu, F. Shen, Yong Xia, Yefa Yang (2016)
Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment.Anti-cancer agents in medicinal chemistry, 16 9
(Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology [Internet]. 2014;146:1691–1700.e3. https://linkinghub.elsevier.com/retrieve/pii/S0016508514002431)
Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology [Internet]. 2014;146:1691–1700.e3. https://linkinghub.elsevier.com/retrieve/pii/S0016508514002431Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology [Internet]. 2014;146:1691–1700.e3. https://linkinghub.elsevier.com/retrieve/pii/S0016508514002431, Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP. Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology [Internet]. 2014;146:1691–1700.e3. https://linkinghub.elsevier.com/retrieve/pii/S0016508514002431
(Munshi A, Ganesh T, Mohanti B. Radiotherapy in India: History, current scenario and proposed solutions. Indian J Cancer [Internet]. 2019;56:359. http://www.indianjcancer.com/text.asp?2019/56/4/359/268964)
Munshi A, Ganesh T, Mohanti B. Radiotherapy in India: History, current scenario and proposed solutions. Indian J Cancer [Internet]. 2019;56:359. http://www.indianjcancer.com/text.asp?2019/56/4/359/268964Munshi A, Ganesh T, Mohanti B. Radiotherapy in India: History, current scenario and proposed solutions. Indian J Cancer [Internet]. 2019;56:359. http://www.indianjcancer.com/text.asp?2019/56/4/359/268964, Munshi A, Ganesh T, Mohanti B. Radiotherapy in India: History, current scenario and proposed solutions. Indian J Cancer [Internet]. 2019;56:359. http://www.indianjcancer.com/text.asp?2019/56/4/359/268964
Rubel Chakravarty, A. Dash, K. Kothari, M. Pillai, M. Venkatesh (2009)
A novel 188W/188Re electrochemical generator with potential for medical applications, 97
Madhava Mallia, Viju Chirayil, A. Dash (2018)
Improved freeze-dried kit for the preparation of 188ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 137
R. Finn, S. Qin, K. Han, F. Piscaglia, A. Baron, Joong-Won Park, G. Han, J. Jassem, Jean Blanc, A. Vogel, D. Komov, T. Evans, C. Lopez, C. Dutcus, M. Guo, Kenichi Saito, S. Kraljevic, T. Tamai, M. Ren, A. Cheng (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 391
M. Elsayed, B. Cheng, M. Xing, I. Sethi, D. Brandon, D. Schuster, Z. Bercu, J. Galt, Bruce Barron, N. Kokabi (2020)
Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?CardioVascular and Interventional Radiology, 44
(Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, et al. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol [Internet]. 2020;10:43–80. https://linkinghub.elsevier.com/retrieve/pii/S0973688319302403)
Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, et al. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol [Internet]. 2020;10:43–80. https://linkinghub.elsevier.com/retrieve/pii/S0973688319302403Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, et al. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol [Internet]. 2020;10:43–80. https://linkinghub.elsevier.com/retrieve/pii/S0973688319302403, Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, et al. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol [Internet]. 2020;10:43–80. https://linkinghub.elsevier.com/retrieve/pii/S0973688319302403
(El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology [Internet]. 2008;134:1752–63. https://linkinghub.elsevier.com/retrieve/pii/S0016508508004265)
El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology [Internet]. 2008;134:1752–63. https://linkinghub.elsevier.com/retrieve/pii/S0016508508004265El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology [Internet]. 2008;134:1752–63. https://linkinghub.elsevier.com/retrieve/pii/S0016508508004265, El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology [Internet]. 2008;134:1752–63. https://linkinghub.elsevier.com/retrieve/pii/S0016508508004265
((NCCN) NCCN. NCCN Guidelines for patients [Internet]. Natl. Compr. Cancer Netw. Found. 2014. p. 1–96. http://www.nccn.org/patients/guidelines/stage_i_ii_breast/index.html#4/z)
(NCCN) NCCN. NCCN Guidelines for patients [Internet]. Natl. Compr. Cancer Netw. Found. 2014. p. 1–96. http://www.nccn.org/patients/guidelines/stage_i_ii_breast/index.html#4/z(NCCN) NCCN. NCCN Guidelines for patients [Internet]. Natl. Compr. Cancer Netw. Found. 2014. p. 1–96. http://www.nccn.org/patients/guidelines/stage_i_ii_breast/index.html#4/z, (NCCN) NCCN. NCCN Guidelines for patients [Internet]. Natl. Compr. Cancer Netw. Found. 2014. p. 1–96. http://www.nccn.org/patients/guidelines/stage_i_ii_breast/index.html#4/z
M. Volk, S. Vijan, J. Marrero (2008)
A Novel Model Measuring the Harm of Transplanting Hepatocellular Carcinoma Exceeding Milan CriteriaAmerican Journal of Transplantation, 8
(Xu M, Feng M. Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines? Semin Liver Dis [Internet]. 2019;39:043–52. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1676098)
Xu M, Feng M. Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines? Semin Liver Dis [Internet]. 2019;39:043–52. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1676098Xu M, Feng M. Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines? Semin Liver Dis [Internet]. 2019;39:043–52. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1676098, Xu M, Feng M. Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines? Semin Liver Dis [Internet]. 2019;39:043–52. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1676098
(Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther [Internet]. 2016;33:699–714. http://link.springer.com/10.1007/s12325-016-0324-7)
Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther [Internet]. 2016;33:699–714. http://link.springer.com/10.1007/s12325-016-0324-7Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther [Internet]. 2016;33:699–714. http://link.springer.com/10.1007/s12325-016-0324-7, Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther [Internet]. 2016;33:699–714. http://link.springer.com/10.1007/s12325-016-0324-7
W. Lau, E. Lai, T. Leung, S. Yu (2008)
Adjuvant Intra-arterial Iodine-131-labeled Lipiodol for Resectable Hepatocellular Carcinoma: A Prospective Randomized Trial—Update on 5-Year and 10-Year SurvivalAnnals of Surgery, 247
(Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig [Internet]. 2017;30:272–8. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202017000400272&lng=en&tlng=en)
Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig [Internet]. 2017;30:272–8. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202017000400272&lng=en&tlng=enChedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig [Internet]. 2017;30:272–8. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202017000400272&lng=en&tlng=en, Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig [Internet]. 2017;30:272–8. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202017000400272&lng=en&tlng=en
(Szyszko T, Brooks A, Tait P, Rubello D, AL-Nahhas A. Therapy options for treatment of hepatic malignancy. Eur J Nucl Med Mol Imaging [Internet]. 2008;35:1824–6. Available from: http://link.springer.com/10.1007/s00259-008-0798-x)
Szyszko T, Brooks A, Tait P, Rubello D, AL-Nahhas A. Therapy options for treatment of hepatic malignancy. Eur J Nucl Med Mol Imaging [Internet]. 2008;35:1824–6. Available from: http://link.springer.com/10.1007/s00259-008-0798-xSzyszko T, Brooks A, Tait P, Rubello D, AL-Nahhas A. Therapy options for treatment of hepatic malignancy. Eur J Nucl Med Mol Imaging [Internet]. 2008;35:1824–6. Available from: http://link.springer.com/10.1007/s00259-008-0798-x, Szyszko T, Brooks A, Tait P, Rubello D, AL-Nahhas A. Therapy options for treatment of hepatic malignancy. Eur J Nucl Med Mol Imaging [Internet]. 2008;35:1824–6. Available from: http://link.springer.com/10.1007/s00259-008-0798-x
(Kim TH, Park J-W, Kim BH, Kim H, Moon SH, Kim SS, et al. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel) [Internet]. 2019;11. http://www.ncbi.nlm.nih.gov/pubmed/30781391)
Kim TH, Park J-W, Kim BH, Kim H, Moon SH, Kim SS, et al. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel) [Internet]. 2019;11. http://www.ncbi.nlm.nih.gov/pubmed/30781391Kim TH, Park J-W, Kim BH, Kim H, Moon SH, Kim SS, et al. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel) [Internet]. 2019;11. http://www.ncbi.nlm.nih.gov/pubmed/30781391, Kim TH, Park J-W, Kim BH, Kim H, Moon SH, Kim SS, et al. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel) [Internet]. 2019;11. http://www.ncbi.nlm.nih.gov/pubmed/30781391
(Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol [Internet]. 2019;25:6041–52. https://www.wjgnet.com/1007-9327/full/v25/i40/6041.htm)
Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol [Internet]. 2019;25:6041–52. https://www.wjgnet.com/1007-9327/full/v25/i40/6041.htmDi Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol [Internet]. 2019;25:6041–52. https://www.wjgnet.com/1007-9327/full/v25/i40/6041.htm, Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol [Internet]. 2019;25:6041–52. https://www.wjgnet.com/1007-9327/full/v25/i40/6041.htm
(Zhang L, Ding J, Li H-Y, Wang Z-H, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta - Rev Cancer [Internet]. 2020;1874:188441. https://linkinghub.elsevier.com/retrieve/pii/S0304419X20301608)
Zhang L, Ding J, Li H-Y, Wang Z-H, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta - Rev Cancer [Internet]. 2020;1874:188441. https://linkinghub.elsevier.com/retrieve/pii/S0304419X20301608Zhang L, Ding J, Li H-Y, Wang Z-H, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta - Rev Cancer [Internet]. 2020;1874:188441. https://linkinghub.elsevier.com/retrieve/pii/S0304419X20301608, Zhang L, Ding J, Li H-Y, Wang Z-H, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta - Rev Cancer [Internet]. 2020;1874:188441. https://linkinghub.elsevier.com/retrieve/pii/S0304419X20301608
(Omagari K, Ohba K, Kadokawa Y, Hazama H, Masuda JI, Kinoshita H, et al. Comparison of the grade evaluated by “Liver damage” of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatol Res [Internet]. 2006;34:266–72. https://linkinghub.elsevier.com/retrieve/pii/S1386634606000052)
Omagari K, Ohba K, Kadokawa Y, Hazama H, Masuda JI, Kinoshita H, et al. Comparison of the grade evaluated by “Liver damage” of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatol Res [Internet]. 2006;34:266–72. https://linkinghub.elsevier.com/retrieve/pii/S1386634606000052Omagari K, Ohba K, Kadokawa Y, Hazama H, Masuda JI, Kinoshita H, et al. Comparison of the grade evaluated by “Liver damage” of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatol Res [Internet]. 2006;34:266–72. https://linkinghub.elsevier.com/retrieve/pii/S1386634606000052, Omagari K, Ohba K, Kadokawa Y, Hazama H, Masuda JI, Kinoshita H, et al. Comparison of the grade evaluated by “Liver damage” of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma. Hepatol Res [Internet]. 2006;34:266–72. https://linkinghub.elsevier.com/retrieve/pii/S1386634606000052
(Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol [Internet]. 2009;10:25–34. http://www.ncbi.nlm.nih.gov/pubmed/19095497)
Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol [Internet]. 2009;10:25–34. http://www.ncbi.nlm.nih.gov/pubmed/19095497Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol [Internet]. 2009;10:25–34. http://www.ncbi.nlm.nih.gov/pubmed/19095497, Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol [Internet]. 2009;10:25–34. http://www.ncbi.nlm.nih.gov/pubmed/19095497
(Chakravarty R, Dash A, Kothari K, Pillai MRA, Venkatesh M. A novel 188W/188Re electrochemical generator with potential for medical applications. Radiochim Acta [Internet]. 2009;97. https://www.degruyter.com/document/doi/10.1524/ract.2009.1612/html)
Chakravarty R, Dash A, Kothari K, Pillai MRA, Venkatesh M. A novel 188W/188Re electrochemical generator with potential for medical applications. Radiochim Acta [Internet]. 2009;97. https://www.degruyter.com/document/doi/10.1524/ract.2009.1612/htmlChakravarty R, Dash A, Kothari K, Pillai MRA, Venkatesh M. A novel 188W/188Re electrochemical generator with potential for medical applications. Radiochim Acta [Internet]. 2009;97. https://www.degruyter.com/document/doi/10.1524/ract.2009.1612/html, Chakravarty R, Dash A, Kothari K, Pillai MRA, Venkatesh M. A novel 188W/188Re electrochemical generator with potential for medical applications. Radiochim Acta [Internet]. 2009;97. https://www.degruyter.com/document/doi/10.1524/ract.2009.1612/html
(Kumar A, Srivastava DN, Chau TTM, Long HD, Bal C, Chandra P, et al. Inoperable Hepatocellular Carcinoma: Transarterial 188 Re HDD–Labeled Iodized Oil for Treatment—Prospective Multicenter Clinical Trial. Radiology [Internet]. 2007;243:509–19. http://pubs.rsna.org/doi/10.1148/radiol.2432051246)
Kumar A, Srivastava DN, Chau TTM, Long HD, Bal C, Chandra P, et al. Inoperable Hepatocellular Carcinoma: Transarterial 188 Re HDD–Labeled Iodized Oil for Treatment—Prospective Multicenter Clinical Trial. Radiology [Internet]. 2007;243:509–19. http://pubs.rsna.org/doi/10.1148/radiol.2432051246Kumar A, Srivastava DN, Chau TTM, Long HD, Bal C, Chandra P, et al. Inoperable Hepatocellular Carcinoma: Transarterial 188 Re HDD–Labeled Iodized Oil for Treatment—Prospective Multicenter Clinical Trial. Radiology [Internet]. 2007;243:509–19. http://pubs.rsna.org/doi/10.1148/radiol.2432051246, Kumar A, Srivastava DN, Chau TTM, Long HD, Bal C, Chandra P, et al. Inoperable Hepatocellular Carcinoma: Transarterial 188 Re HDD–Labeled Iodized Oil for Treatment—Prospective Multicenter Clinical Trial. Radiology [Internet]. 2007;243:509–19. http://pubs.rsna.org/doi/10.1148/radiol.2432051246
(Zhang S-Y, Zhu G-Y, Li G, Zhang Y-B, Geng J-H. Application of stereotactic body radiation therapy to cancer liver metastasis. Cancer Lett [Internet]. 2016;379:225–9. https://linkinghub.elsevier.com/retrieve/pii/S0304383515006606)
Zhang S-Y, Zhu G-Y, Li G, Zhang Y-B, Geng J-H. Application of stereotactic body radiation therapy to cancer liver metastasis. Cancer Lett [Internet]. 2016;379:225–9. https://linkinghub.elsevier.com/retrieve/pii/S0304383515006606Zhang S-Y, Zhu G-Y, Li G, Zhang Y-B, Geng J-H. Application of stereotactic body radiation therapy to cancer liver metastasis. Cancer Lett [Internet]. 2016;379:225–9. https://linkinghub.elsevier.com/retrieve/pii/S0304383515006606, Zhang S-Y, Zhu G-Y, Li G, Zhang Y-B, Geng J-H. Application of stereotactic body radiation therapy to cancer liver metastasis. Cancer Lett [Internet]. 2016;379:225–9. https://linkinghub.elsevier.com/retrieve/pii/S0304383515006606
V. Vilgrain, H. Pereira, E. Assenat, B. Guiu, Alina-Diana Ilonca, G. Pageaux, A. Sibert, M. Bouattour, R. Lebtahi, Wassim Allaham, H. Barraud, V. Laurent, E. Mathias, J. Bronowicki, J. Tasu, R. Perdrisot, C. Silvain, R. Gérolami, O. Mundler, J. Seitz, V. Vidal, C. Aubé, F. Oberti, O. Couturier, I. Brenot-Rossi, J. Raoul, A. Sarran, C. Costentin, E. Itti, A. Luciani, R. Adam, M. Lewin, D. Samuel, M. Ronot, Aurélia Dinut, L. Castéra, G. Chatellier (2017)
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.The Lancet. Oncology, 18 12
(Lepareur N, Ardisson V, Noiret N, Boucher E, Raoul J-L, Clément B, et al. Automation of labelling of Lipiodol with high-activity generator-produced 188Re. Appl Radiat Isot [Internet]. 2011;69:426–30. https://linkinghub.elsevier.com/retrieve/pii/S096980431000429X)
Lepareur N, Ardisson V, Noiret N, Boucher E, Raoul J-L, Clément B, et al. Automation of labelling of Lipiodol with high-activity generator-produced 188Re. Appl Radiat Isot [Internet]. 2011;69:426–30. https://linkinghub.elsevier.com/retrieve/pii/S096980431000429XLepareur N, Ardisson V, Noiret N, Boucher E, Raoul J-L, Clément B, et al. Automation of labelling of Lipiodol with high-activity generator-produced 188Re. Appl Radiat Isot [Internet]. 2011;69:426–30. https://linkinghub.elsevier.com/retrieve/pii/S096980431000429X, Lepareur N, Ardisson V, Noiret N, Boucher E, Raoul J-L, Clément B, et al. Automation of labelling of Lipiodol with high-activity generator-produced 188Re. Appl Radiat Isot [Internet]. 2011;69:426–30. https://linkinghub.elsevier.com/retrieve/pii/S096980431000429X
J. Soldera, S. Balbinot, R. Balbinot, A. Cavalcanti (2016)
Diagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer ProtocolClinical Medicine Insights. Gastroenterology, 9
(Padhy AK, Dondi M. A Report on the Implementation Aspects of the International Atomic Energy Agency’s First Doctoral Coordinated Research Project, “Management of Liver Cancer Using Radionuclide Methods With Special Emphasis on Trans-Arterial Radio-Conjugate Therapy and Inte. Semin Nucl Med [Internet]. 2008;38:S5–12. https://linkinghub.elsevier.com/retrieve/pii/S0001299807001183)
Padhy AK, Dondi M. A Report on the Implementation Aspects of the International Atomic Energy Agency’s First Doctoral Coordinated Research Project, “Management of Liver Cancer Using Radionuclide Methods With Special Emphasis on Trans-Arterial Radio-Conjugate Therapy and Inte. Semin Nucl Med [Internet]. 2008;38:S5–12. https://linkinghub.elsevier.com/retrieve/pii/S0001299807001183Padhy AK, Dondi M. A Report on the Implementation Aspects of the International Atomic Energy Agency’s First Doctoral Coordinated Research Project, “Management of Liver Cancer Using Radionuclide Methods With Special Emphasis on Trans-Arterial Radio-Conjugate Therapy and Inte. Semin Nucl Med [Internet]. 2008;38:S5–12. https://linkinghub.elsevier.com/retrieve/pii/S0001299807001183, Padhy AK, Dondi M. A Report on the Implementation Aspects of the International Atomic Energy Agency’s First Doctoral Coordinated Research Project, “Management of Liver Cancer Using Radionuclide Methods With Special Emphasis on Trans-Arterial Radio-Conjugate Therapy and Inte. Semin Nucl Med [Internet]. 2008;38:S5–12. https://linkinghub.elsevier.com/retrieve/pii/S0001299807001183
Z. Jia, G. Jiang, F. Tian, Chunfu Zhu, X. Qin (2016)
A Systematic Review on the Safety and Effectiveness of yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Tumor ThrombosisSaudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association, 22
M. Chedid, C. Kruel, M. Pinto, T. Grezzana-Filho, I. Leipnitz, C. Kruel, L. Scaffaro, A. Chedid (2017)
HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND OPERATIVE MANAGEMENTArquivos Brasileiros de Cirurgia Digestiva : ABCD, 30
J. Kim, K. Han, Jong Lee, Y. Paik, S. Ahn, Jong Lee, K. Lee, C. Chon, Y. Moon (2006)
Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular CarcinomaClinical Cancer Research, 12
R. Tateishi, H. Yoshida, Y. Matsuyama, N. Mine, Y. Kondo, M. Omata (2008)
Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic reviewHepatology International, 2
A. Bujold, C. Massey, John Kim, J. Brierley, C. Cho, R. Wong, R. Dinniwell, Z. Kassam, J. Ringash, B. Cummings, J. Sykes, M. Sherman, J. Knox, L. Dawson (2013)
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 13
F. Pons, M. Varela, J. Llovet (2005)
Staging systems in hepatocellular carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association, 7 1
(Lohar S, Jadhav S, Chakravarty R, Chakraborty S, Sarma HD, Dash A. A kit based methodology for convenient formulation of 166Ho-Chitosan complex for treatment of liver cancer. Appl Radiat Isot [Internet]. 2020;161:109161. https://linkinghub.elsevier.com/retrieve/pii/S0969804320302906)
Lohar S, Jadhav S, Chakravarty R, Chakraborty S, Sarma HD, Dash A. A kit based methodology for convenient formulation of 166Ho-Chitosan complex for treatment of liver cancer. Appl Radiat Isot [Internet]. 2020;161:109161. https://linkinghub.elsevier.com/retrieve/pii/S0969804320302906Lohar S, Jadhav S, Chakravarty R, Chakraborty S, Sarma HD, Dash A. A kit based methodology for convenient formulation of 166Ho-Chitosan complex for treatment of liver cancer. Appl Radiat Isot [Internet]. 2020;161:109161. https://linkinghub.elsevier.com/retrieve/pii/S0969804320302906, Lohar S, Jadhav S, Chakravarty R, Chakraborty S, Sarma HD, Dash A. A kit based methodology for convenient formulation of 166Ho-Chitosan complex for treatment of liver cancer. Appl Radiat Isot [Internet]. 2020;161:109161. https://linkinghub.elsevier.com/retrieve/pii/S0969804320302906
Joo Oh, D. Sinn, G. Choi, J. Kim, J. Joh, T. Kang, D. Hyun, W. Kang, G. Gwak, Y. Paik, J. Lee, K. Koh, S. Paik, M. Choi (2020)
Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteriaAnnals of Surgical Treatment and Research, 99
(Boucher E, Garin E, Guylligomarc’h A, Olivié D, Boudjema K, Raoul J-L. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol [Internet]. 2007;82:76–82. https://linkinghub.elsevier.com/retrieve/pii/S0167814006005925)
Boucher E, Garin E, Guylligomarc’h A, Olivié D, Boudjema K, Raoul J-L. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol [Internet]. 2007;82:76–82. https://linkinghub.elsevier.com/retrieve/pii/S0167814006005925Boucher E, Garin E, Guylligomarc’h A, Olivié D, Boudjema K, Raoul J-L. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol [Internet]. 2007;82:76–82. https://linkinghub.elsevier.com/retrieve/pii/S0167814006005925, Boucher E, Garin E, Guylligomarc’h A, Olivié D, Boudjema K, Raoul J-L. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol [Internet]. 2007;82:76–82. https://linkinghub.elsevier.com/retrieve/pii/S0167814006005925
(Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for Primary and Metastatic Liver Cancer. Semin Radiat Oncol [Internet]. 2011;21:294–302. https://linkinghub.elsevier.com/retrieve/pii/S1053429611000464)
Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for Primary and Metastatic Liver Cancer. Semin Radiat Oncol [Internet]. 2011;21:294–302. https://linkinghub.elsevier.com/retrieve/pii/S1053429611000464Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for Primary and Metastatic Liver Cancer. Semin Radiat Oncol [Internet]. 2011;21:294–302. https://linkinghub.elsevier.com/retrieve/pii/S1053429611000464, Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for Primary and Metastatic Liver Cancer. Semin Radiat Oncol [Internet]. 2011;21:294–302. https://linkinghub.elsevier.com/retrieve/pii/S1053429611000464
(Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med [Internet]. 2016;41:1–7. http://www.ncbi.nlm.nih.gov/pubmed/26402131)
Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med [Internet]. 2016;41:1–7. http://www.ncbi.nlm.nih.gov/pubmed/26402131Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med [Internet]. 2016;41:1–7. http://www.ncbi.nlm.nih.gov/pubmed/26402131, Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med [Internet]. 2016;41:1–7. http://www.ncbi.nlm.nih.gov/pubmed/26402131
(Ibrahim S-M, Lewandowski R-J, Sato K-T, Gates V-L, Kulik L, Mulcahy M-F, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol [Internet]. 2008;14:1664–9. http://www.ncbi.nlm.nih.gov/pubmed/18350597)
Ibrahim S-M, Lewandowski R-J, Sato K-T, Gates V-L, Kulik L, Mulcahy M-F, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol [Internet]. 2008;14:1664–9. http://www.ncbi.nlm.nih.gov/pubmed/18350597Ibrahim S-M, Lewandowski R-J, Sato K-T, Gates V-L, Kulik L, Mulcahy M-F, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol [Internet]. 2008;14:1664–9. http://www.ncbi.nlm.nih.gov/pubmed/18350597, Ibrahim S-M, Lewandowski R-J, Sato K-T, Gates V-L, Kulik L, Mulcahy M-F, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol [Internet]. 2008;14:1664–9. http://www.ncbi.nlm.nih.gov/pubmed/18350597
(Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol [Internet]. 2013;31:1631–9. http://ascopubs.org/doi/10.1200/JCO.2012.44.1659)
Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol [Internet]. 2013;31:1631–9. http://ascopubs.org/doi/10.1200/JCO.2012.44.1659Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol [Internet]. 2013;31:1631–9. http://ascopubs.org/doi/10.1200/JCO.2012.44.1659, Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol [Internet]. 2013;31:1631–9. http://ascopubs.org/doi/10.1200/JCO.2012.44.1659
Lei Jiang, Hui Tan, C. Panje, Hao-jun Yu, Y. Xiu, Hongcheng Shi (2014)
Role of 18F-FDG PET/CT Imaging in Intrahepatic CholangiocarcinomaClinical Nuclear Medicine, 41
(Lee EW, Alanis L, Cho S-K, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol [Internet]. 2016;17:472. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2016.17.4.472)
Lee EW, Alanis L, Cho S-K, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol [Internet]. 2016;17:472. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2016.17.4.472Lee EW, Alanis L, Cho S-K, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol [Internet]. 2016;17:472. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2016.17.4.472, Lee EW, Alanis L, Cho S-K, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol [Internet]. 2016;17:472. https://www.kjronline.org/DOIx.php?id=10.3348/kjr.2016.17.4.472
(Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol [Internet]. 2016;34:460–8. https://ascopubs.org/doi/10.1200/JCO.2015.64.2710)
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol [Internet]. 2016;34:460–8. https://ascopubs.org/doi/10.1200/JCO.2015.64.2710Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol [Internet]. 2016;34:460–8. https://ascopubs.org/doi/10.1200/JCO.2015.64.2710, Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol [Internet]. 2016;34:460–8. https://ascopubs.org/doi/10.1200/JCO.2015.64.2710
(Jia H, Yan D, Xiao Q, Zhang G. Correlations of ultrasonic features with severity of liver cancer and p16 expression in patients with liver cancer. Neoplasma [Internet]. 2019;66:149–54. http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=5883&category_id=147&option=com_virtuemart)
Jia H, Yan D, Xiao Q, Zhang G. Correlations of ultrasonic features with severity of liver cancer and p16 expression in patients with liver cancer. Neoplasma [Internet]. 2019;66:149–54. http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=5883&category_id=147&option=com_virtuemartJia H, Yan D, Xiao Q, Zhang G. Correlations of ultrasonic features with severity of liver cancer and p16 expression in patients with liver cancer. Neoplasma [Internet]. 2019;66:149–54. http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=5883&category_id=147&option=com_virtuemart, Jia H, Yan D, Xiao Q, Zhang G. Correlations of ultrasonic features with severity of liver cancer and p16 expression in patients with liver cancer. Neoplasma [Internet]. 2019;66:149–54. http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=5883&category_id=147&option=com_virtuemart
T. Szyszko, A. Brooks, P. Tait, D. Rubello, A. Al-Nahhas (2008)
Therapy options for treatment of hepatic malignancyEuropean Journal of Nuclear Medicine and Molecular Imaging, 35
J. Titano, A. Noor, Edward Kim (2017)
Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer StagesSeminars in Interventional Radiology, 34
(Ravichandran R, Binukumar J, Sreeram R, Arunkumar L. An overview of radioactive waste disposal procedures of a nuclear medicine department. J Med Phys [Internet]. 2011;36:95. http://www.jmp.org.in/text.asp?2011/36/2/95/79692)
Ravichandran R, Binukumar J, Sreeram R, Arunkumar L. An overview of radioactive waste disposal procedures of a nuclear medicine department. J Med Phys [Internet]. 2011;36:95. http://www.jmp.org.in/text.asp?2011/36/2/95/79692Ravichandran R, Binukumar J, Sreeram R, Arunkumar L. An overview of radioactive waste disposal procedures of a nuclear medicine department. J Med Phys [Internet]. 2011;36:95. http://www.jmp.org.in/text.asp?2011/36/2/95/79692, Ravichandran R, Binukumar J, Sreeram R, Arunkumar L. An overview of radioactive waste disposal procedures of a nuclear medicine department. J Med Phys [Internet]. 2011;36:95. http://www.jmp.org.in/text.asp?2011/36/2/95/79692
M. Landman, I. Feurer, I. Feurer, C. Pinson, D. Moore, D. Moore (2011)
Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?HPB : the official journal of the International Hepato Pancreato Biliary Association, 13 11
A. Munshi, T. Ganesh, B. Mohanti (2019)
Radiotherapy in India: History, current scenario and proposed solutionsIndian Journal of Cancer, 56
(Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, et al. The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol [Internet]. 2014;4:S3–26. https://linkinghub.elsevier.com/retrieve/pii/S0973688314002710)
Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, et al. The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol [Internet]. 2014;4:S3–26. https://linkinghub.elsevier.com/retrieve/pii/S0973688314002710Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, et al. The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol [Internet]. 2014;4:S3–26. https://linkinghub.elsevier.com/retrieve/pii/S0973688314002710, Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, et al. The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol [Internet]. 2014;4:S3–26. https://linkinghub.elsevier.com/retrieve/pii/S0973688314002710
B. Carr, H. Akkız, O. Üsküdar, K. Yalcin, V. Guerra, S. Kuran, Ümit Karaoğullarından, E. Altıntaş, A. Özakyol, S. Tokmak, T. Ballı, M. Yücesoy, Halil Bahçeci, Abdulalh Ülkü, Tolga Akçam, K. Polat, Nazım Ekinci, H. Şimşek, N. Örmeci, A. Sonsuz, M. Demir, M. Kılıç, A. Uygun, A. Demir, A. Delik, B. Arslan, F. Doran, S. Yılmaz, Y. Tokat (2018)
HCC with low- and normal-serum alpha-fetoprotein levels.Clinical practice, 15 1
R. Yeung, T. Chapman, S. Bowen, S. Apisarnthanarax (2017)
Proton beam therapy for hepatocellular carcinomaExpert Review of Anticancer Therapy, 17
(Esquinas PL, Shinto A, Kamaleshwaran KK, Joseph J, Celler A. Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans. EJNMMI Phys [Internet]. 2018;5:30. https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-018-0227-6)
Esquinas PL, Shinto A, Kamaleshwaran KK, Joseph J, Celler A. Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans. EJNMMI Phys [Internet]. 2018;5:30. https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-018-0227-6Esquinas PL, Shinto A, Kamaleshwaran KK, Joseph J, Celler A. Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans. EJNMMI Phys [Internet]. 2018;5:30. https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-018-0227-6, Esquinas PL, Shinto A, Kamaleshwaran KK, Joseph J, Celler A. Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans. EJNMMI Phys [Internet]. 2018;5:30. https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-018-0227-6
S. Lagana, M. Salomao, F. Bao, R. Moreira, J. Lefkowitch, H. Remotti (2012)
Utility of an Immunohistochemical Panel Consisting of Glypican-3, Heat-shock Protein-70, and Glutamine Synthetase in the Distinction of Low-grade Hepatocellular Carcinoma From Hepatocellular AdenomaApplied Immunohistochemistry & Molecular Morphology, 21
(Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance practice guidelines and real-life practice. J Clin Gastroenterol [Internet]. 2016;50:120–33. https://journals.lww.com/00004836-201602000-00008)
Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance practice guidelines and real-life practice. J Clin Gastroenterol [Internet]. 2016;50:120–33. https://journals.lww.com/00004836-201602000-00008Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance practice guidelines and real-life practice. J Clin Gastroenterol [Internet]. 2016;50:120–33. https://journals.lww.com/00004836-201602000-00008, Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance practice guidelines and real-life practice. J Clin Gastroenterol [Internet]. 2016;50:120–33. https://journals.lww.com/00004836-201602000-00008
R. Lewandowski, R. Salem (2006)
Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.Seminars in interventional radiology, 23 1
A. Padhy, M. Dondi (2008)
A report on the implementation aspects of the International Atomic Energy Agency's first doctoral coordinated research project, "Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry".Seminars in nuclear medicine, 38 2
(Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol [Internet]. 2017;34:109–15. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1602709)
Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol [Internet]. 2017;34:109–15. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1602709Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol [Internet]. 2017;34:109–15. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1602709, Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol [Internet]. 2017;34:109–15. http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1602709
C. Costentin (2017)
Le dépistage du carcinome hépatocellulairePresse Medicale, 46
R. Ravichandran, J. Binukumar, R. Sreeram, LS Arunkumar (2011)
An overview of radioactive waste disposal procedures of a nuclear medicine departmentJournal of Medical Physics / Association of Medical Physicists of India, 36
J. Greiser, W. Weigand, M. Freesmeyer (2019)
Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the LiverPharmaceuticals, 12
(Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study). J Gastrointest Cancer [Internet]. 2020. http://link.springer.com/10.1007/s12029-020-00502-z)
Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study). J Gastrointest Cancer [Internet]. 2020. http://link.springer.com/10.1007/s12029-020-00502-zHirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study). J Gastrointest Cancer [Internet]. 2020. http://link.springer.com/10.1007/s12029-020-00502-z, Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study). J Gastrointest Cancer [Internet]. 2020. http://link.springer.com/10.1007/s12029-020-00502-z
A. Singal, M. Volk, A. Waljee, R. Salgia, P. Higgins, M. Rogers, J. Marrero (2009)
Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosisAlimentary Pharmacology & Therapeutics, 30
S. Shiina, R. Tateishi, M. Imamura, T. Teratani, Y. Koike, Shin'pei Sato, S. Obi, F. Kanai, N. Kato, H. Yoshida, M. Omata, K. Koike (2012)
Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factorsLiver International, 32
(Wang L, Lu JJ, Yin W, Lang J. Perspectives on Patient Access to Radiation Oncology Facilities and Services in Mainland China. Semin Radiat Oncol [Internet]. 2017;27:164–8. https://linkinghub.elsevier.com/retrieve/pii/S1053429616300674)
Wang L, Lu JJ, Yin W, Lang J. Perspectives on Patient Access to Radiation Oncology Facilities and Services in Mainland China. Semin Radiat Oncol [Internet]. 2017;27:164–8. https://linkinghub.elsevier.com/retrieve/pii/S1053429616300674Wang L, Lu JJ, Yin W, Lang J. Perspectives on Patient Access to Radiation Oncology Facilities and Services in Mainland China. Semin Radiat Oncol [Internet]. 2017;27:164–8. https://linkinghub.elsevier.com/retrieve/pii/S1053429616300674, Wang L, Lu JJ, Yin W, Lang J. Perspectives on Patient Access to Radiation Oncology Facilities and Services in Mainland China. Semin Radiat Oncol [Internet]. 2017;27:164–8. https://linkinghub.elsevier.com/retrieve/pii/S1053429616300674
(Reiss KA, Yu S, Mamtani R, Mehta R, D’Addeo K, Wileyto EP, et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol [Internet]. 2017;35:3575–81. https://ascopubs.org/doi/10.1200/JCO.2017.73.8245)
Reiss KA, Yu S, Mamtani R, Mehta R, D’Addeo K, Wileyto EP, et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol [Internet]. 2017;35:3575–81. https://ascopubs.org/doi/10.1200/JCO.2017.73.8245Reiss KA, Yu S, Mamtani R, Mehta R, D’Addeo K, Wileyto EP, et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol [Internet]. 2017;35:3575–81. https://ascopubs.org/doi/10.1200/JCO.2017.73.8245, Reiss KA, Yu S, Mamtani R, Mehta R, D’Addeo K, Wileyto EP, et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol [Internet]. 2017;35:3575–81. https://ascopubs.org/doi/10.1200/JCO.2017.73.8245
A. Zhu, Yoon-Koo Kang, C. Yen, R. Finn, P. Galle, J. Llovet, E. Assenat, G. Brandi, M. Pracht, Ho Lim, K. Rau, K. Motomura, I. Ohno, P. Merle, B. Daniele, D. Shin, G. Gerken, C. Borg, J. Hiriart, T. Okusaka, M. Morimoto, Y. Hsu, P. Abada, M. Kudo (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology, 20 2
N. Massarweh, H. El‐Serag (2017)
Epidemiology of Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaCancer Control : Journal of the Moffitt Cancer Center, 24
N. Sanuki, A. Takeda, Y. Oku, Tomikazu Mizuno, Yosuke Aoki, Takahisa Eriguchi, S. Iwabuchi, E. Kunieda (2014)
Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patientsActa Oncologica, 53
Tom Cheung, P. Kwok, S. Chan, C. Cheung, A. Lee, V. Lee, Hoi-Ching Cheng, N. Chia, C. Chong, Tak-wing Lai, A. Law, M. Luk, C. Tong, T. Yau (2018)
Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular CarcinomaLiver Cancer, 7
(Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost‐effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco‐regional therapy for hepatocellular carcinoma within Milan criteria? HPB [Internet]. 2011;13:783–91. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15303816)
Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost‐effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco‐regional therapy for hepatocellular carcinoma within Milan criteria? HPB [Internet]. 2011;13:783–91. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15303816Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost‐effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco‐regional therapy for hepatocellular carcinoma within Milan criteria? HPB [Internet]. 2011;13:783–91. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15303816, Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost‐effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco‐regional therapy for hepatocellular carcinoma within Milan criteria? HPB [Internet]. 2011;13:783–91. https://linkinghub.elsevier.com/retrieve/pii/S1365182X15303816
Ashish Kumar, S. Acharya, S. Singh, A. Arora, R. Dhiman, R. Aggarwal, A. Anand, P. Bhangui, Y. Chawla, S. Gupta, V. Dixit, A. Duseja, N. Kalra, P. Kar, S. Kulkarni, Rakesh Kumar, Manoj Kumar, R. Madhavan, V. Prasad, A. Mukund, A. Nagral, Dipanjan Panda, S. Paul, P. Rao, M. Rela, M. Sahu, V. Saraswat, Samir Shah, Shalimar, Praveen Sharma, S. Taneja, M. Wadhawan (2020)
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.Journal of clinical and experimental hepatology, 10 1
(Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe PJ, Beels L, Maes A. PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: A systematic review. Int J Mol Sci [Internet]. 2019;20:4886. Available from: https://www.mdpi.com/1422-0067/20/19/4886)
Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe PJ, Beels L, Maes A. PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: A systematic review. Int J Mol Sci [Internet]. 2019;20:4886. Available from: https://www.mdpi.com/1422-0067/20/19/4886Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe PJ, Beels L, Maes A. PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: A systematic review. Int J Mol Sci [Internet]. 2019;20:4886. Available from: https://www.mdpi.com/1422-0067/20/19/4886, Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe PJ, Beels L, Maes A. PSMA-targeting positron emission agents for imaging solid tumors other than non-prostate carcinoma: A systematic review. Int J Mol Sci [Internet]. 2019;20:4886. Available from: https://www.mdpi.com/1422-0067/20/19/4886
E. Lee, L. Alanis, S. Cho, S. Saab (2016)
Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature ReviewKorean Journal of Radiology, 17
(Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res [Internet]. 2015;45:n/a-n/a. http://doi.wiley.com/10.1111/hepr.12464)
Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res [Internet]. 2015;45:n/a-n/a. http://doi.wiley.com/10.1111/hepr.12464Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res [Internet]. 2015;45:n/a-n/a. http://doi.wiley.com/10.1111/hepr.12464, Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res [Internet]. 2015;45:n/a-n/a. http://doi.wiley.com/10.1111/hepr.12464
(Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, et al. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med [Internet]. 2005;46:60–6. http://www.ncbi.nlm.nih.gov/pubmed/15632035)
Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, et al. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med [Internet]. 2005;46:60–6. http://www.ncbi.nlm.nih.gov/pubmed/15632035Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, et al. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med [Internet]. 2005;46:60–6. http://www.ncbi.nlm.nih.gov/pubmed/15632035, Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, et al. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med [Internet]. 2005;46:60–6. http://www.ncbi.nlm.nih.gov/pubmed/15632035
MD Raoul, MD Bretagne, MD Caucanas, MD Pariente, MD Boyer, MD Paris, MD Michel, P. Bourguef, MD Victor, MD Therain, MD Lejeune, MD Lemaire, MD Collef, R. Duvauferrier, MD Puech, MD Viala, MD L'Hosfe, Mdii Poisonnier, Mdr Guiry (1992)
Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131‐labeled lipiodolCancer, 69
U. Grewal, G. Walia, R. Bakshi, Siddharth Chopra (2018)
Hepatitis B and C Viruses, Their Coinfection and Correlations in Chronic Liver Disease Patients: A Tertiary Care Hospital StudyInternational Journal of Applied and Basic Medical Research, 8
(Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc [Internet]. 2018;16:29. https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-018-0112-0)
Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc [Internet]. 2018;16:29. https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-018-0112-0Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc [Internet]. 2018;16:29. https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-018-0112-0, Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc [Internet]. 2018;16:29. https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-018-0112-0
C. Chen (2020)
Role of External Beam Radiotherapy in Hepatocellular Carcinoma.Clinics in liver disease, 24 4
Ashish Kumar, S. Acharya, S. Singh, V. Saraswat, A. Arora, A. Duseja, M. Goenka, D. Jain, P. Kar, M. Kumar, V. Kumaran, K. Mohandas, Dipanjan Panda, S. Paul, J. Ramachandran, H. Ramesh, P. Rao, Samir Shah, H. Sharma, R. Thandassery (2014)
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.Journal of clinical and experimental hepatology, 4 Suppl 3
F. Giammarile, L. Bodei, C. Chiesa, G. Flux, F. Forrer, F. Kraeber-Bodéré, B. Brans, B. Lambert, M. Konijnenberg, F. Borson‐Chazot, J. Tennvall, M. Luster, Oncology Therapy (2011)
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compoundsEuropean Journal of Nuclear Medicine and Molecular Imaging, 38
S. Yoon, B. Ryoo, So Lee, Jong Kim, J. Shin, Jiyun An, H. Lee, Y. Lim (2018)
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical TrialJAMA Oncology, 4
(Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis [Internet]. 2020;24:701–17. https://linkinghub.elsevier.com/retrieve/pii/S108932612030057X)
Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis [Internet]. 2020;24:701–17. https://linkinghub.elsevier.com/retrieve/pii/S108932612030057XChen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis [Internet]. 2020;24:701–17. https://linkinghub.elsevier.com/retrieve/pii/S108932612030057X, Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis [Internet]. 2020;24:701–17. https://linkinghub.elsevier.com/retrieve/pii/S108932612030057X
Joong-Won Park, Ji Kim, Chong Dang, Sunghyun Lee, Do Kim, Hyeong-Jun Kim, Hwi-Young Kim, S. Park, Joo Shim, Jeong-Hoon Lee, Ho Lim, K. Suh, Yang Ko, Seong Kim, J. Kim, Y. Yun, D. Jeong, J. Chung, Y. Koh, Kyeong Kim, Young Kim, In Lee, J. Seong, C. Kay, Mi-Sook Kim, Tae Kim, Hee Park, Sun Bae, S. Yoon, W. Jang (2019)
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular CarcinomaKorean Journal of Radiology, 20
(Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, et al. Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers (Basel) [Internet]. 2018;10:367. http://www.mdpi.com/2072-6694/10/10/367)
Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, et al. Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers (Basel) [Internet]. 2018;10:367. http://www.mdpi.com/2072-6694/10/10/367Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, et al. Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers (Basel) [Internet]. 2018;10:367. http://www.mdpi.com/2072-6694/10/10/367, Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, et al. Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers (Basel) [Internet]. 2018;10:367. http://www.mdpi.com/2072-6694/10/10/367
(Haug AR. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging [Internet]. 2017;61:292–300. http://www.ncbi.nlm.nih.gov/pubmed/28686007)
Haug AR. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging [Internet]. 2017;61:292–300. http://www.ncbi.nlm.nih.gov/pubmed/28686007Haug AR. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging [Internet]. 2017;61:292–300. http://www.ncbi.nlm.nih.gov/pubmed/28686007, Haug AR. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging [Internet]. 2017;61:292–300. http://www.ncbi.nlm.nih.gov/pubmed/28686007
Tim Labeur, K. Cieslak, T. Gulik, R. Takkenberg, S. Velden, M. Lam, H. Klümpen, R. Bennink, O. Delden (2020)
The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinomaNuclear Medicine Communications, 41
M. Reinders, M. Smits, C. Roekel, A. Braat (2019)
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.Seminars in nuclear medicine, 49 3
L. Tommaso, M. Spadaccini, M. Donadon, N. Personeni, A. Elamin, A. Aghemo, A. Lleo (2019)
Role of liver biopsy in hepatocellular carcinomaWorld Journal of Gastroenterology, 25
Hepatocellular carcinoma (HCC) is a global killer with preponderance in Asian and African countries. It poses a challenge for successful management in less affluent or developing nations like India, with large populations and limited infrastructures. This review aims to assess the available options and future directions for management of HCC applicable to such countries. While summarizing current and emerging clinical strategies for detection, staging and therapy of the disease, it highlights radioisotope- and radioactivity-based strategies as part of an overall program. Using the widely accepted Barcelona Clinic Liver Cancer (BCLC) staging system as a base, it evaluates the applicability of different therapeutic approaches and their synergistic combination(s) in the context of a patient-specific dynamic results-based strategy. It distills the conclusions of multiple HCC management-focused consensus recommendations to provide a picture of clinical strategies, especially radiation-related approaches. Additionally, it discusses the logistical and economic feasibility of these approaches in the context of the limitations of the burdened public health infrastructure in India (and like nations) and highlights possible strategies both at the clinical level and in terms of an administrative health policy on HCC to provide the maximum possible benefit to the widest swathe of the affected population.
Oncology and Therapy – Springer Journals
Published: Dec 1, 2021
Keywords: BCLC; Embolization; Hepatocellular carcinoma; Liver cancer; Radiation therapy; SIRT; TARE
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.